

FEATURING:

Premium Exhibits

Visit exhibits from industry, health information technology companies, NCCN Member Institutions, and more.

General Poster Sessions I & II

Posters will be presented during breakfast, lunch, and breaks on Friday and Saturday.

Poster Tours

12:30 PM | Friday and Saturday

Experts will lead guided tours of the posters and discuss research highlights.

NEW First Timers Breakfast

7:30 – 8:30 AM | Friday

First-time conference attendees can enjoy giveaways, enter to win prizes, and meet with NCCN staff and leaders. Return attendees are also welcome!

NEW Headshot Station | Booth #628

12:00 – 3:30 PM | Friday and Saturday

Smile! Stop by to have your headshot taken by a professional photographer. Photos will be taken on a first-come, first-served basis.

Reimbursement Resource Room

Connect with organizations about patient support resources and services to mitigate reimbursement challenges.

Patient Advocacy Pavilion

Visit patient advocacy kiosks representing a range of disease types and learn about resources for patients.

Visit NCCN Booth #624 and NCCN Foundation Booth #622

- Learn about NCCN resources for clinicians and patients.
- Drop off completed Poster Session Form(s) to enter to win an Amazon Echo Show 5.
- Visit at least six booths and drop off a completed Exhibitor Passport form to receive a free prize while supplies last.
- Complete the NCCN Trends™ Survey to enter to win Beats Studio Buds.

Product Theaters Magnolia 7, 8, 9

Hear about new products and programs in oncology.



Annual 2024 Conference

EXHIBIT GUIDE

Cypress 2

Friday, April 5 ▶ 7:30 AM – 3:35 PM

Saturday, April 6 ▶ 7:30 AM – 3:30 PM

View Exhibit Hall
Floor Plan



Wi-Fi Access
Network: NCCN2024
Password: NCCN2024

NCCN.org/conference | #NCCN2024



CREATING HOPE THROUGH INNOVATION

At Eisai, everything we do is guided by a simple principle: patients and their families come first. We spend time with them. We listen and we learn about their lives, their desires and their greatest needs. *We call this human health care or hhc*, giving first thoughts to patients and their families and helping increase the benefits health care provides.

Our hhc mission is what drives us to discover innovative solutions and therapies that help address unmet needs within the communities that we seek to serve.

Eisai is proud to support the National Comprehensive Cancer Network.

hhc
human health care

TO LEARN MORE, PLEASE VISIT [US.EISAI.COM](https://us.eisai.com)



Annual 2024 Conference

Commercial Sponsors

Platinum

[Eisai](#)
[Incyte Corporation](#)

Gold

[Johnson & Johnson](#)
[Regeneron](#)

Silver

[AstraZeneca](#)

Bronze

[BeiGene](#)
[GSK](#)
[Jazz Pharmaceuticals](#)
[Servier Pharmaceuticals](#)

 **DARZALEX[®]**
(daratumumab)
injection for intravenous infusion
100 mg/5 mL, 400 mg/20 mL

 **DARZALEX Faspro[®]**
(daratumumab and hyaluronidase-fihj)
Injection for subcutaneous use | 1,800mg/30,000units

Watch KOL expert series at darzalexhcp.com



Kenneth Shain, MD, PhD



Visit the AstraZeneca Booth at NCCN 2024!



IMFINZI[®]
durvalumab
Injection for Intravenous Use 50 mg/mL

IMJUDO[®]
tremelimumab-actl
Injection for Intravenous Use 20 mg/mL



CALQUENCE[®]
acalabrutinib 100 mg tablets



TAGRISSO[®]
osimertinib



Lynparza[®]
olaparib
tablets 150 mg



Truqap[™]
capiwasertib
160 mg • 200 mg tablets



Please scan for complete Prescribing Information, including Boxed WARNINGS and Medication Guide, or visit www.ENHERTUPI.com

ENHERTU[®]
fam-trastuzumab deruxtecan-nxki
20 mg/mL INJECTION FOR INTRAVENOUS USE

Please see Important Safety Information and full Prescribing Information, including Boxed WARNINGS, and Medication Guide, available at our booth & at www.ENHERTUPI.com

Daiichi-Sankyo

AstraZeneca

ENHERTU[®] is a registered trademark of Daiichi Sankyo Company, Limited.
©2024 Daiichi Sankyo, Inc. and AstraZeneca, PP-US-ENB-3126 02/24

For more information, please visit us at
www.astrazeneca-us.com

CALQUENCE, IMFINZI, IMJUDO, LYNPARZA and TAGRISSO are registered trademarks, and TRUQAP is a trademark of the AstraZeneca group of companies.
©2024 AstraZeneca. All rights reserved. US-84711 Last Updated 02/24

AstraZeneca



National Comprehensive
Cancer Network[®]


FREE for your mobile device




Virtual Library of NCCN Guidelines App


- Easy access to NCCN Guidelines[®], global resources, and NCCN Guidelines for Patients[®]
- Hyperlinks within the Guidelines
- Ability to quickly share Guidelines
- Optimized search and viewing options

Download today! NCCN.org/apps





Cancer breakthroughs take time.



**That's why we work at
such a furious pace.**

At Johnson & Johnson, we are working on developing treatments that work with the natural defenses of the body in order to halt the growth of cancers such as multiple myeloma. Everything we do gets us closer to a future where cancer is a thing of the past.

Johnson&Johnson

© Janssen Biotech, Inc. 2024 02/24 cp-426399v1

STAY UP TO DATE WITH THE DATA



DARZALEX Faspro[®]

(daratumumab and hyaluronidase-fihj)

Injection for subcutaneous use | 1,800mg/30,000units

▶ See more at [DARZALEXHCP.com](https://www.darzalexhcp.com)



janssen



PHARMACEUTICAL COMPANIES OF

Johnson & Johnson

Exhibit Hall

EXHIBITORS

Acrotech Biopharma, Inc.	601
Astellas	700
AstraZeneca	803
BeiGene	716
CVS Specialty	617
Daiichi Sankyo, Inc.	606
ECG Management Consultants	602
Eisai	701
Eli Lilly and Company	822
EMD Serono	620
Fennec Pharmaceuticals	709
Foundation Medicine	900
Genmab	904
Geron	916
Incyte	703
InformedDNA	924
Jazz Pharmaceuticals	902
Johnson & Johnson	723
Karyopharm Therapeutics, Inc.	600
Kite, A Gilead Company	604
La Roche-Posay a L'OREAL company	621
LeanTaaS	819
Merck & Co., Inc.	808
Novartis Pharmaceuticals Corporation – Commercial	607
Novartis Pharmaceuticals Corporation – Medical	708
ONCOassist	926
Oncology Nutrition - Registered Dietitians / Nutritionist	824
OneOme	922
Oxford BioDynamics	603
Pfizer Oncology	823
PharmaEssentia	605
PreciseDX	704
Regeneron	800
Servier Pharmaceuticals	718
SkinCure Oncology	722
Stemline, a Menarini Group Company – Commercial	801
Stemline, a Menarini Group Company – Medical	711
Sun Pharma	707
Taiho Oncology	817

NCCN MEMBER INSTITUTIONS


Mayo Clinic	724
Moffitt Cancer Center	623
Roswell Park Comprehensive Cancer Center	625

REIMBURSEMENT RESOURCE ROOM

Astellas	R-4
BeiGene	R-1
Johnson & Johnson	R-3
Spectrum Pharmaceuticals	R-2

PATIENT ADVOCACY PAVILION

Association of Cancer Care Centers (ACCC)	A14
---	-----



REGISTRATION & GENERAL SESSION



Bladder Cancer Advocacy Network (BCAN)	A5
Cholangiocarcinoma Foundation	A11
Crossroads4Hope	A9
Global Colon Cancer Association	A1
GO2 for Lung Cancer	A16
Head and Neck Cancer Alliance	A4
Imerman Angels	A8
The Leukemia & Lymphoma Society	A3
LiveLung	A6
Say YES to Hope	A13
Sharsheret	A10
Tigerlily Foundation	A2

GENERAL SESSION



Triage Cancer	A15
Veterans Prostate Cancer Awareness, Inc.	A7
Young Adult Survivors United (YASU)	A12

JNCCN PUBLISHER

Harborside-BroadcastMed	619
-------------------------	-----

NCCN

NCCN Foundation	622
NCCN General Information	624
Headshot Station	628

Non-CE Product Theaters

These non-CE presentations can be viewed on the Virtual Event Platform.
Attendees can also view in-person in **Magnolia 7, 8, 9**.
No pre-registration is required.

Friday, April 5

7:50 – 8:20 AM

Key Considerations When Choosing a First-Line Treatment Option for Unresectable Hepatocellular Carcinoma

Presented by AstraZeneca

12:00 – 12:30 PM

The Era of Multi-cancer Early Detection Testing: A Paradigm Shift in Cancer Screening

Presented by Exact Sciences Corporation

12:35 - 1:05 PM

Matters of the Heart: Diagnosing and Treating Light-Chain Amyloidosis (AL)

Sponsored by Alexion, AstraZeneca Rare Disease

Saturday, April 6

7:50 – 8:20 AM

NCCN Foundation: Empowering Patients and Research Innovation

12:00 – 12:30 PM

Understanding the Role of Advanced Practice Providers in the Management of Low-risk Myelodysplastic Syndromes (MDS)

Presented by Bristol Myers Squibb

12:35 – 1:05 PM

Expanding Options for Patients with HER2-Low mBC

Presented by Daiichi Sankyo, Inc. and AstraZeneca

Patient Advocacy Pavilion Sponsors

Emerald

[AstraZeneca](#)

[BeiGene](#)

Coherus

[Eisai](#)

[Incyte Corporation](#)

[Johnson & Johnson](#)

Topaz

[AbbVie](#)

Cencora

[GSK](#)

Lantheus

My fellow colleagues,


In patients with polycythemia vera (PV), the threat of thrombosis is real, and it is within our power to reduce it. Studies have demonstrated that elevated Hct increases a patient's thrombotic risk.^{1,2} As shown in the graph below from the CYTO-PV study, the rate of CV death and major thrombosis was 4 times as high among patients whose Hct was maintained between 45% and 50% compared with those whose Hct was maintained strictly below 45%.^{3*}



Prithviraj Bose, MD
MPN Expert

This article, sponsored by Incyte, is based on a paid interview with Prithviraj Bose, MD.

Patients with Hct between 45% and 50% had a 4-fold higher rate of cardiovascular death and major thrombosis^{3†}



One of the main goals of treatment for our PV patients should be to maintain strict Hct control.³ From my clinical perspective, it's important for my high-risk PV patients to remain below that 45% threshold, ideally without any need for phlebotomy. It's a red flag to me when my high-risk patients on HU still need 3 or more phlebotomies a year. Frequent phlebotomies in patients on cytoreductive therapy signal a need to optimize treatment.⁴

The CYTO-PV study has substantially informed the way I manage my PV patients. These data challenge the notion that PV is a cancer with a benign course.

Prithviraj Bose

*Multicenter, randomized, and controlled trial that assessed the benefit/risk profile of cytoreductive therapy with PBT or HU aimed at maintaining Hct at <45% vs maintaining Hct at 45% to 50% in 365 adult patients with PV. The composite primary endpoint was the time until cardiovascular death or major thrombosis.³

†A significant increase in the risk of cardiovascular death and major thrombosis was demonstrated with Hct levels between 45% and 50% compared with Hct levels <45% (HR, 3.91; 95% CI, 1.45-10.53; P=0.007).

CI=confidence interval; CV=cardiovascular; CYTO-PV=Cytoreductive Therapy in Polycythemia Vera; Hct=hematocrit; HR=hazard ratio; HU=hydroxyurea; PBT=phlebotomy.

References: 1. Marchioli R, Finazzi G, Landolfi R, et al. *J Clin Oncol*. 2005;23(10):2224-2232. 2. Barbui T, Finazzi G, Falanga A. *Blood*. 2013;122(13):2176-2184. 3. Marchioli R, Finazzi G, Specchia G, et al; for CYTO-PV Collaborative Group. *N Engl J Med*. 2013;368(11):22-33. 4. NCCN Clinical Practice Guidelines in Oncology (NCCN Guidelines®) for Myeloproliferative Neoplasms V.3.2022. © National Comprehensive Cancer Network, Inc. 2022. All rights reserved.



Incyte and the Incyte logo are registered trademarks of Incyte.
© 2023, Incyte. MAT-HEM-03189 02/23



For more of Dr Bose's perspective, scan here to read his white paper "*Optimizing the Management of Patients With Polycythemia Vera*"





PUSH THE BOUNDS OF SCIENCE MAKE LIFE-CHANGING MEDICINES

Regeneron is a leading biotechnology company that invents, develops and commercializes life-transforming medicines for serious diseases. Founded and led for 35 years by physician-scientists, our unique ability to repeatedly translate science into medicine has led to numerous FDA-approved treatments and product candidates in development.

Learn more at www.regeneron.com

REGENERON[®]

APPROVED IN A 4TH INDICATION

**EVEN MORE
PATIENTS
MAY BE RIGHT
FOR BRUKINSA**



REVIEW THE TRIALS SUPPORTING
THE LATEST APPROVAL

BeiGene and BRUKINSA are registered trademarks
owned by BeiGene, Ltd. or its affiliates.
© BeiGene, Ltd. 2023 All Rights Reserved.
0522-BRU-PRC-038 1/2023



For the treatment of newly diagnosed, IC-ineligible acute myeloid leukemia (AML)

COULD WAITING FOR TEST RESULTS GIVE YOUR PATIENTS MORE TIME?

Does molecular profiling help drive your treatment selection in newly diagnosed AML? **It should.** Mutated *IDH1* (*mIDH1*) is an oncogenic driver in up to 10% of AML cases.¹ More importantly, *mIDH1* is an actionable target for treatment. That's why both the NCCN Clinical Practice Guidelines in Oncology (NCCN Guidelines[®]) and the ASH-CAP Guidelines recommend performing molecular and cytogenetic analyses to identify *IDH1* mutations in patients with AML.^{2,3} Further, the NCCN Guidelines[®] recommend expediting these analyses.²

So the next time you have a patient with newly diagnosed, IC-ineligible AML, test for *IDH1* mutation status BEFORE choosing treatment—your first step to treatment selection could be your patient's first step to better outcomes.



Learn more at [AMLTreatmentOption.com](https://www.AMLTreatmentOption.com)

ASH, American Society of Hematology; CAP, College of American Pathologists; IC, induction chemotherapy; *IDH1*, isocitrate dehydrogenase-1; NCCN, National Comprehensive Cancer Network.

References: 1. Molenaar RJ, Maciejewski JP, Wilmink JW, van Noorden CJF. Wild-type and mutated *IDH1/2* enzymes and therapy responses. *Oncogene*. 2018;37(15):1949-1960. doi:10.1038/s41388-017-0077-z 2. Referenced with permission from the NCCN Clinical Practice Guidelines in Oncology (NCCN Guidelines[®]) for Acute Myeloid Leukemia V.2.2022. © National Comprehensive Cancer Network, Inc. 2022. All rights reserved. Accessed October 18, 2022. To view the most recent and complete version of the guideline, go online to NCCN.org. NCCN makes no warranties of any kind whatsoever regarding their content, use or application and disclaims any responsibility for their application or use in any way. 3. Arber DA, Borowitz MJ, Cessna M, et al. Initial diagnostic workup of acute leukemia: guideline from the College of American Pathologists and the American Society of Hematology. *Arch Pathol Lab Med*. 2017;141(10):1342-1393. doi:10.5858/arpa.2016-0504-CP

Together with GSK Oncology offers a variety of access and reimbursement services in **one location** for all GSK oncology products.



Reimbursement support

- Insurance benefits investigation
- Information about prior authorizations
- Guidance on insurance denials or coverage requirements
- Coding and claims assistance for products and related services

Together with GSK Oncology does not guarantee coverage or payer reimbursement for product treatment or administration. Healthcare professionals should confirm information directly with payers



Access assistance

- Co-pay assistance for eligible commercially insured patients
- Patient assistance program that makes free product available to eligible patients
- Information about alternative funding sources



For program terms and eligibility and to obtain a **Together with GSK Oncology** Enrollment Form, visit [TogetherwithGSKOncology.com](https://www.togetherwithgskoncology.com) or call 1-844-4GSK-ONC (1-844-447-5662), Monday-Friday, (8AM TO 8PM ET)

Connect with **Together with GSK Oncology** today

Trademarks are owned by or licensed to the GSK group of companies.



Not actual patients

 **LENVIMA**[®]
(lenvatinib) capsules | 10 mg and 4 mg

**Visit [LENVIMAHCP.com](https://www.lenvimahcp.com) for
more information**



LENVIMA[®] is a registered trademark used by Eisai Inc. under license from Eisai R&D Management Co., Ltd.
© 2023 Eisai Inc. All rights reserved. Printed in USA/April 2023 LENV-US9401

About Our Exhibitors

Acrotech Biopharma, Inc.

Booth #601

Founded in 2018, Acrotech Biopharma Inc. was formed as a global platform to commercialize innovative proprietary medications. The company aims to launch scientifically advanced products to address unmet needs and deliver value to patients as well as all healthcare stakeholders. Acrotech aspires to be a patient focused, research-based organization that strives to launch treatments which are accessible to patients that need them.

Astellas

Booth #700

Astellas is committed to turning innovative science into medical solutions that bring value and hope to patients and their families. Keeping our focus on addressing unmet medical needs and conducting our business with ethics and integrity enables us to improve the health of people throughout the U.S. and around the world.

AstraZeneca

Booth #803

AstraZeneca is a global, science-led biopharmaceutical company that focuses on the discovery, development, and commercialization of prescription medicines in Oncology, Rare Diseases and BioPharmaceuticals, including Cardiovascular, Renal & Metabolism, and Respiratory & Immunology. Based in Cambridge, UK, AstraZeneca operates in over 100 countries and its innovative medicines are used by millions of patients worldwide. Please visit www.astrazeneca-us.com and follow us on social media @AstraZeneca.

BeiGene

Booth #716

BeiGene is a global oncology company that is discovering and developing innovative treatments that are more affordable and accessible to cancer patients worldwide. With a broad portfolio, we are expediting development of our diverse pipeline of novel therapeutics through our internal capabilities and collaborations. We are committed to radically improving access to medicines for far more patients who need them. Our growing global team of more than 10,000 colleagues spans five continents, with administrative offices in Basel, Beijing, and Cambridge, U.S.

CVS Specialty

Booth #617

Personalized Specialty Pharmacy Services

Our commitment to helping patients and their physicians manage complex drug therapies by delivering individualized patient care with compassion and dedication has made us one of the leading specialty pharmacies in the country. To learn more or to enroll patients, call 1-800-238-7828.

Daiichi Sankyo, Inc.

Booth #606

ECG Management Consultants

Booth #602

With knowledge and expertise built over the course of 50-plus years, ECG is a national consulting firm that is redefining healthcare together with its clients. ECG offers a broad range of strategic, financial, operational, and technology-related consulting services. ECG is an industry leader, offering specialized expertise to hospitals, health systems, medical groups, academic medical centers, children's hospitals, ambulatory surgery centers, investors, and payers/health plans. As an affiliated partner of Siemens Healthineers, ECG's subject matter experts have a proven track record of delivering results fueled by top talent and technology.

Eisai

Booth #701

At Eisai Inc., human health care (hhc) is our goal. We give our first thoughts to patients and their families and help to increase the benefits health care provides. As the U.S. pharmaceutical subsidiary of Tokyo-based Eisai Co., Ltd., we have a passionate commitment to patient care that is the driving force behind our efforts to help address unmet medical needs. We are a fully integrated pharmaceutical business with discovery, clinical, and marketing capabilities. Our key areas of focus include oncology and neurology (dementia-related diseases and neurodegenerative diseases). To learn more about Eisai Inc., please visit us at www.eisai.com/US and follow us on [Twitter](#) and [LinkedIn](#).

Eli Lilly and Company

Booth #822

Lilly is a global healthcare leader that unites caring with discovery to create medicines that make life better for people around the world. Across the globe, Lilly employees work to discover and bring life-changing medicines to those who need them, improve the understanding and management of disease, and give back to communities through philanthropy and volunteerism.

EMD Serono

Booth #620

EMD Serono is a science-led organization of curious minds dedicated to delivering transformative medicines that can make a difference in the lives of people affected by cancer.

We apply our scientific curiosity to tackling challenging tumor types in key areas—gastrointestinal (GI), genitourinary (GU), and thoracic cancers—where there are unmet needs and where we believe we can drive transformation of patient care.

SILVER

BRONZE

PLATINUM

About Our Exhibitors

By relentlessly pursuing potential solutions to even the most complex cancers, we hope to illuminate a path to scientific breakthroughs that impact patient care.

Fennec Pharmaceuticals **Booth #709**

Fennec Pharmaceuticals is a biotechnology company dedicated to improving the lives of children with cancer who experience hearing loss as a result of chemotherapy.

Foundation Medicine **Booth #900**

Your Essential Partner in Cancer Care

Foundation Medicine is a pioneer in molecular profiling for cancer, working to shape the future of clinical care and research. We collaborate with a broad range of partners across the cancer community and strive to set the standard for quality, scientific excellence, and regulatory leadership. Our deep understanding of cancer biology helps physicians make informed treatment decisions for their patients and empowers researchers to develop new medicines. We are driven to help our partners find answers and take action to transform cancer care.

Genmab **Booth #904**

Genmab is an international biotechnology company with a core purpose to improve the lives of people with cancer and other serious diseases. To help develop and deliver novel therapies to patients, Genmab has formed 20+ strategic partnerships with biotechnology and pharmaceutical companies. Genmab's proprietary pipeline includes bispecific T-cell engagers, next-generation immune checkpoint modulators, effector function enhanced antibodies and antibody-drug conjugates. Visit us at Genmab.com or [Twitter.com/Genmab](https://twitter.com/Genmab).

Geron **Booth #916**

Geron is a late-stage clinical biopharmaceutical company focused on development and commercialization of therapies in hematologic malignancies. We are committed to pursuing discoveries with the potential to extend and enrich the lives of patients.

Harborside-BroadcastMed **Booth #619**

Harborside, a division of BroadcastMed, is a leader in medical publishing and communications and a destination that has earned the trust of doctors, advanced practitioners, medical societies, medical affairs professionals, and health-care marketers. Its mission is to advance the field of oncology through better information. Its reputation for high-quality,

diverse offerings and partnerships with ASCO, NCCN, APSHO, and other organizations, has led to an unmatched level of trust from clinicians.

Incyte **Booth #703**

Incyte is a Wilmington, Delaware-based, global biopharmaceutical company focused on finding solutions for serious unmet medical needs through the discovery, development, and commercialization of proprietary therapeutics. For additional information on Incyte, please visit Incyte.com and follow @Incyte.

InformedDNA **Booth #924**

Established in 2007 as the nation's pioneer telehealth Genetic Counseling company, InformedDNA is an unrivaled leader in genetic counseling with a force of fully licensed, board-certified genetics experts that cover all subspecialties. We consistently earn market-leading Net Promoter Scores >75 and Provider Satisfaction Scores over 95%. Through innovative solutions that revolutionize the application of genomic insights, we enhance patient care, improve outcomes for all, and shape the future of precision health. InformedDNA is headquartered in St. Petersburg, FL. Learn more about the benefits of partnering with InformedDNA at InformedDNA.com

Jazz Pharmaceuticals **Booth #902**

Jazz Pharmaceuticals is focused on developing life-changing medicines for people with serious diseases with limited or no options, to allow patients to live their lives fully. By transforming biopharmaceutical discoveries into novel medicines, we are working to give people the opportunity to redefine what's possible – to make the "small wins" big again.

We are a global biopharmaceutical company with a diverse portfolio of products for adults and children, with expertise in two key therapeutic areas: neuroscience and oncology. In oncology, we investigate medicines for hard-to-treat cancers with the purpose of transforming the lives of patients and their families.

Johnson & Johnson **Booth #723**

At Johnson & Johnson, we believe health is everything. Our strength in healthcare innovation empowers us to build a world where complex diseases are prevented, treated, and cured, where treatments are smarter and less invasive, and solutions are personal. Through our expertise in Innovative Medicine and MedTech, we are uniquely positioned to innovate across the full spectrum of healthcare solutions today to deliver the breakthroughs of tomorrow, and profoundly impact

PLATINUM

BRONZE

GOLD



SARCLISA[®] (isatuximab-irfc)

Injection for IV use | 500 mg/25 mL, 100 mg/5 mL

See the latest data for **SARCLISA + Kd**

Explore the full results of the
IKEMA phase 3 trial at
sarclisahcp.com



Kd=Kyprolis (carfilzomib) and dexamethasone

Now in our 19th year, **the Bladder Cancer Advocacy Network** has committed more than \$10 million in research funding to end bladder cancer. And we're just getting started.



www.BCAN.org




Empower your patients.

Too many CLL patients are navigating their disease alone.

Please consider connecting your patients with the vital support, education, and other valuable resources that CLL Society can offer as the **world's leading authority** on chronic lymphocytic leukemia.



cllsociety.org Knowledge. Guidance. Compassion.



CLL SOCIETY

About Our Exhibitors

health for humanity. Learn more at www.jnj.com/ or at www.janssen.com/johnson-johnson-innovative-medicine. Follow us at @JanssenUS and @JNJInnovMed.

Karyopharm Therapeutics, Inc. Booth #600

Karyopharm Therapeutics is a commercial-stage pharmaceutical company pioneering novel first-in-class cancer therapies and dedicated to the discovery, development, and commercialization of drugs to treat cancer. We believe in the extraordinary – in the dedication to positively impact patient lives and treat cancer. We are recognized leaders in XPO1 inhibition, which has the potential to engage the cell's innate ability to fight cancer. Patients embody extraordinary and deserve the same from those in their communities. That is why we choose to spend our time where it has the most significant impact: Multiple Myeloma, Endometrial Cancer, Myelofibrosis, and Diffuse Large B-Cell Lymphoma.

Kite, A Gilead Company Booth #604

Kite, a Gilead Company, is a global biopharmaceutical company based in Santa Monica, California, focused on cell therapy to treat and potentially cure cancer. As the global cell therapy leader, Kite has treated more patients with CAR T-cell therapy than any other company. Kite has the largest in-house cell therapy manufacturing network in the world, spanning process development, vector manufacturing, clinical trial supply and commercial product manufacturing. For more information on Kite, please visit www.kitepharma.com.

La Roche-Posay a L'OREAL Company Booth #621

Company Description: We are committed to providing educational resources for patients and their caregivers throughout the cancer journey. Recommended by 90,000 dermatologists worldwide, we partner with dermatologists to stay at the forefront of skincare science, pioneering cutting-edge topics like skin's microbiome. With over 750+ studies and 25 years of extensive research, we are committed to developing safe and effective products that are dermatologist developed and tested.

LeanTaaS Booth #819

LeanTaaS is the leading provider of AI-powered and cloud-based capacity management, staffing, and patient flow software for health systems. Our iQueue products for operating rooms, infusion centers, and inpatient units are trusted by 1,000+ hospitals and centers across 185 health systems. Our solutions use

Lean principles and AI/ML predictive and prescriptive analytics to forecast future demand based on historical data, recent pattern shifts, and real-time insights. They help staff and providers act quickly, confidently, and decisively to avoid operational bottlenecks before they even happen.

Merck & Co., Inc. Booth #808

At Merck, our goal is to translate breakthrough science into innovative oncology medicines to help people with cancer. The potential to bring new hope to people with cancer drives our purpose and our commitment. As part of our focus on cancer, Merck is committed to clinical research with one of the largest development programs in the industry across more than 30 tumor types.

Novartis Pharmaceuticals Corporation Booth #607 & #708

Novartis is an innovative medicines company. Every day, we work to reimagine medicine to improve and extend people's lives so that patients, healthcare professionals and societies are empowered in the face of serious disease. Our medicines reach more than 250 million people worldwide. Reimagine medicine with us: Visit us at www.novartis.com and connect with us on [LinkedIn](#), [Facebook](#), [X/Twitter](#) and [Instagram](#).

ONCOassist Booth #926

ONCOassist is a comprehensive suite of decision support tools developed by oncology professionals, for oncology professionals. It includes a range of breakthrough tools designed to manage patient care effectively.

Oncology Nutrition – Registered Dietitians/Nutritionist Booth #824

Oncology Nutrition Dietetic Practice Group (ON-DPG) of the Academy of Nutrition and Dietetics (AND) fosters excellence in oncology nutrition via an evidence-based nutrition care process. The ON-DPG also promotes education, research and advocacy through publications, symposiums, and webinars. Attendees will gain education materials on nutrition screening and malnutrition diagnosing as up to 80% of cancer patients become malnourished during their cancer continuum. The ON-DPG endorses the vital role of a Registered Dietitian Nutritionist (RDN) as the nutrition expert on the multidisciplinary care team.

OneOme Booth #922

OneOme – cofounded by the Mayo Clinic – is a leader in precision medicine, providing pharmacogenomic

About Our Exhibitors

solutions, population-level value-based care analyses and clinical decision support solutions. OneOme aims to impact patient safety, reduce the overall cost of care, and improve patient health outcomes. OneOme recently introduced RightMed for Oncology, a first-of-its-kind germline pharmacogenomics panel focused on medications used as chemotherapy and supportive care. This compliments single and double-gene tests for oncology practices, including a DPYD test covering variants *2A, *13, HapB3, c.2846A>T, & c.557A>G. www.oneome.com

Oxford BioDynamics **Booth #603**

Oxford Biodynamics, Plc (AIM:OBD) is a global biotech company advancing personalized healthcare by developing & commercializing precision medicine tests for life-changing diseases. Our portfolio of clinical tests and research tools based on EpiSwitch® technology aims to help physicians better understand their patient's clinical status for therapeutic response, disease prognostication, and early cancer detection. Its flagship products are the EpiSwitch® CiRT (Checkpoint Inhibitor Response Test) and EpiSwitch® PSE (EpiSwitch Prostate Screening test) blood tests. CiRT is a predictive immune response profile for immuno-oncology checkpoint inhibitor treatments. PSE predicts a patient's current likelihood of having prostate cancer with 94% accuracy.

Pfizer Oncology **Booth #823**

At Pfizer Oncology, we are at the forefront of a new era in cancer care. Our industry-leading portfolio and extensive pipeline includes game-changing mechanisms of action to attack cancer from multiple angles, including antibody-drug conjugates (ADCs), small molecules, bispecifics and other immunotherapies. We are focused on delivering transformative therapies in some of the world's most common cancers, including breast cancer, genitourinary cancer, and hematologic malignancies, as well as melanoma, gastrointestinal, gynecological, and thoracic cancers, which includes lung cancer. Driven by science, we are committed to accelerating breakthroughs to extend and improve patients' lives.

PharmaEssentia **Booth #605**

PharmaEssentia, based in Taipei, Taiwan, is a rapidly growing biopharmaceutical innovator. Leveraging deep expertise and proven scientific principles, the company aims to deliver effective new biologics for challenging diseases in the areas of hematology and oncology, with one approved product and a diversifying pipeline. Founded in 2003, the company is now expanding its global presence with operations in the U.S., Japan, China and Korea. Visit our www.pharmaessentia.com/ to learn more.

PreciseDx **Booth #704**

PreciseDx is innovating oncology diagnostics, leveraging Artificial Intelligence (AI) for revolutionary, morphology-driven, disease analysis. PreciseBreast™ is an in vitro test for early-stage breast cancer that calculates a composite risk of recurrence score based on a proprietary algorithm. PreciseBreast™ leverages AI technology within our Morphology Feature Array® to evaluate the recurrence risk of early-stage breast cancer much faster than traditional testing and with greater reproducibility and precision than any other technology currently utilized in cancer care. PreciseBreast™ is performed on digital scans without the need for tissue specimen or wet lab and can also use traditional H&E-stained slides.

Regeneron **Booth #800**

GOLD

Regeneron is a leading biotechnology company that invents, develops, and commercializes life-transforming medicines for people with serious diseases. Founded and led for nearly 35 years by physician-scientists, our unique ability to repeatedly translate science into medicine has led to numerous FDA-approved treatments and candidates in development. Regeneron is accelerating and improving the traditional drug development process through our proprietary VelociSuite® technologies, and through research initiatives such as the Regeneron Genetics Center. Visit www.Regeneron.com to learn more.

Servier Pharmaceuticals **Booth #718**

BRONZE

Servier is a global leader in oncology focused on delivering meaningful therapeutic progress for the patients it serves. Governed by a non-profit foundation, Servier approaches innovation with a long-term vision, free of influence from investors and outside pressure to chase short-term monetary targets.

As a leader in oncology, Servier has significantly accelerated its investment in difficult and hard-to-treat cancers, with more than 50% of its research and development dedicated to delivering significant advances in areas of high unmet need throughout oncology with the potential to change the lives of the patients it serves. Within these areas, Servier is the leader in mutant IDH inhibition, with the first ever mutant IDH1 inhibitor approved in the U.S. and the European Union, and the company continues to drive the science behind targeted mutant IDH inhibition.

SkinCure Oncology **Booth #722**

About Our Exhibitors

Spectrum Pharmaceuticals

Table #R2

Spectrum Pharmaceuticals, Inc., a subsidiary of Assertio Holdings, Inc., is a leading commercial pharmaceutical company bringing differentiated products to patients. We have a robust portfolio of branded prescription medications. The company has grown through business development including acquisitions, licensing, and mergers. To learn more, visit www.assertiotx.com.

Stemline a Menarini Group Company

Booth #801 & #711

Stemline Therapeutics, a part of the Menarini Group, is focused on the development and commercialization of novel oncology therapeutics. The goal of our dedicated team of scientists, specialists, researchers, and developers is to build a leading biopharmaceutical company focused on improving the lives of cancer patients by developing and commercializing novel first-in-class therapeutics.

Sun Pharma

Booth #707

Sun Pharma is the world's fourth largest specialty generics company with presence in Specialty, Generics and Consumer Healthcare products. It is the largest pharmaceutical company in India and is

a leading generic company in the U.S. and Global Emerging Markets. Sun's high-growth Global Specialty portfolio spans innovative products in dermatology, ophthalmology, and onco-dermatology and accounts for over 16% of company sales. The company's vertically integrated operations deliver high-quality medicines, trusted by physicians and consumers in over 100 countries. Its manufacturing facilities are spread across six continents. Sun Pharma is proud of its multicultural workforce drawn from over 50 nations.

Taiho Oncology

Booth #817

Taiho Oncology specializes in the development and commercialization of orally administered anti-cancer agents for various tumor types. Taiho Oncology has a robust pipeline of small molecule clinical candidates targeting solid tumor and hematological malignancies, with additional candidates in pre-clinical development. Taiho Oncology is a subsidiary of Taiho Pharmaceutical Co., Ltd. which is part of Otsuka Holdings Co., Ltd. Taiho Oncology is headquartered in Princeton, New Jersey and oversees its parent company's European and Canadian operations, which are located in Zug, Switzerland and Oakville, Ontario, Canada.

Join an elite, mission-driven team where your impact matters.

ROSWELL PARK HAS IMMEDIATE OPENINGS FOR THE FOLLOWING POSITIONS

Chief Pharmacy Officer & Senior Executive Director

Director of Breast Imaging

Chief of Nuclear Medicine & Theranostics

Veterinary Research Pathologist

Assistant Professor of Oncology – Leukemia

Sarcoma Oncology, Assistant to Full Professor

Palliative Care Physician



“

I looked for a cancer center with world-class facilities and resources, where they design clinical trials and prioritize immunotherapy research. I intend to make Roswell Park a world leader in innovative cellular therapy.”

– Renier Brentjens, MD, PhD
Deputy Director and Chair, Department of Medicine

I found the one 



Is Roswell Park the **right one** for you?
APPLY TODAY at RoswellPark.org/FacultyRecruitment



VERITAC-2

2L MBC MONO TRIAL

Now Enrolling

A clinical trial for patients with previously treated ER-positive, HER-negative advanced breast cancer

The VERITAC-2 study is a global, phase 3, randomized open-label study of vepdegestrant (ARV-471) vs fulvestrant in patients with ER+, HER2- advanced breast cancer. Vepdegestrant is a potent, selective, orally bioavailable PROteolysis Targeting Chimeric (PROTAC) small molecule that induces degradation of the ER.



Vepdegestrant is an investigational compound and is not approved for any use. Its safety and efficacy have not been established.

Key Eligibility Criteria

- Women or men with ER-positive, HER-negative advanced breast cancer
- Progression on 1-2 lines of endocrine therapy (ET), one of which had to have been in combination with a CDK4/6i
- Duration of most recent ET of ≥ 6 months prior to progression
- No prior chemotherapy in advanced/metastatic setting

Primary Endpoint

- Progression-free survival by blinded independent central review



Scan here to find a clinical trial site near you.


NCT05654623



Shared knowledge creates **global** solutions

PROJECT528

Your voice **matters**



Take the survey



Patricia

diagnosed at age 26, United States

Learn more at project528.youngsurvival.org | Email: project528@youngsurvival.org

FORCE

Facing Hereditary Cancer EMPOWERED

25 years

CELEBRATING 25 YEARS serving the hereditary cancer community



MANY MUTATIONS. MANY CANCERS. ONE COMMUNITY.

FORCE improves the lives of millions of individuals and families facing hereditary breast, ovarian, pancreatic, prostate, colorectal and endometrial cancers. Our community includes people with a personal or family history of cancer, Lynch syndrome, a BRCA1, BRCA2, ATM, PALB2, CHEK2, PTEN or other inherited gene mutation linked to cancer. We accomplish this through our education, support, advocacy and research efforts.

We are grateful for the important work that you do to help members of the hereditary cancer community make informed decisions about their health. Together, we will ensure that no one faces hereditary cancer alone.

VISIT OUR HEALTHCARE PROVIDER PORTAL

where you can sign up for our quarterly newsletter, order brochures to share with patients, learn about continuing education and research opportunities, access resources to support those with hereditary cancer, and much more.



FacingOurRisk.org



Advanced Breast Cancer (ABC) knows no boundaries, affecting individuals from diverse backgrounds, all over the world. At ABC Global Alliance, we are fostering an inclusive environment where people from different countries and backgrounds can come together, collaborate, and share knowledge and resources to improve and extend the lives of ABC patients worldwide.

The ABC Global Alliance is a non-profit association, a multi-stakeholder platform for all those interested in collaborating on common projects related to Advanced Breast Cancer.

Explore more:

www.abcglobalalliance.org

info@abcglobalalliance.org



@ABCGlobalAll



@ABC-Global-Alliance



@ABCGlobalAll



Leading patients to become active contributors in driving cures for incurable diseases.

- Lifetime personalized support and education
- Meaningful patient-to-patient connections
- Powerful patient data portal

Visit healthtree.org today!





Helping People Find Their Cancer Confidant

Providing comfort and understanding for all cancer fighters, survivors, previvors and caregivers through a personalized, peer-to-peer mentorship program with someone who has been there.



Our Service is Free

Collaboration Opportunities

Imerman Angels is always looking to partner with organizations and groups to continue the fight against cancer, including:

- Hospital & Healthcare Professionals
- Pharmaceutical Companies
- Cancer Partner Organizations
- Academic & Research Organizations
- Employee-Benefit Programs



My situation felt so unique and I couldn't help but feel so alone. But when I discovered this program, I knew I wasn't. I'm truly blessed I found Imerman Angels.



2001 N. Halsted, Ste. 302, Chicago, IL 60614 • 866-IMERMAN (463-7626) • info@imermanangels.org • imermanangels.org

BEE the change!



877-937-7478
www.sayyestohope.org



The World of Advanced Cancer is in OUR Hands

NCCN Member Institutions

Mayo Clinic

Booth #724

Moffitt Cancer Center

Booth #623

Moffitt is dedicated to one lifesaving mission: to contribute to the prevention and cure of cancer. The Tampa-based facility is one of only 56 National Cancer Institute-designated Comprehensive Cancer Centers, a distinction that recognizes Moffitt's scientific excellence, multidisciplinary research, and robust training and education. Moffitt's expert nursing staff is recognized by the American Nurses Credentialing Center with Magnet® status, its highest distinction. With more than 9,000 team members, Moffitt has an economic impact in the state of \$2.4 billion. For more information, call 1-888-MOFFITT (1-888-663-3488), visit MOFFITT.org and follow the momentum on Facebook, Twitter, Instagram and YouTube.

Roswell Park Comprehensive Cancer Center


Booth #625

Founded in 1898 and operating from a 29-acre campus on the Buffalo Niagara Medical Campus near downtown Buffalo, New York, Roswell Park today remains the only comprehensive cancer center designated by the NCI in Upstate NY. In the past year, Roswell Park's team of 4,188 total employees, including 364 faculty members and 855 nurses, cared for more than 46,000 patients. Roswell Park helps set international standards in cancer care through its role as a founding member of the National Comprehensive Cancer Network, and consistently earns patient-satisfaction scores that are among the highest in the country.

Changing the way cancer is treated.

Kite's singular focus is cell therapy to treat and potentially cure cancer.

We proudly serve patients around the globe from our manufacturing facilities in California, Maryland and the Netherlands.



Patient Advocacy Pavilion

Anal Cancer Foundation

virtual only

The Anal Cancer Foundation is dedicated to empowering anal cancer patients and accelerating prevention and treatment methods that eliminate anal cancer and HPV.

Our mission is to:

- Highlight the relevance of HPV in contracting cancer
- Accelerate a cure for the 5% of all cancers, including anal cancer, caused by HPV
- Advocate for prevention methods that will end anal cancer and HPV-related cancers, including gender-neutral vaccination
- Support anal cancer survivors, caregivers, scientists, and providers

Association of Cancer Care Centers (ACCC)

Kiosk #A14

The Association of Cancer Care Centers (ACCC) provides education and advocacy for the cancer care community. Founded in 1974, ACCC is a powerful network of more than 40,000 multidisciplinary practitioners from over 1,700 hospitals and practices nationwide. As advances in cancer screening and diagnosis, treatment options, and care delivery models continue to evolve—so has ACCC—adapting its resources to meet the changing needs of the entire oncology care team. For more information, visit acc-cancer.org. Follow us on LinkedIn; read our blog, ACCCBuzz; tune in to our CANCER BUZZ podcast; and view our CANCER BUZZ TV channel.

Bag It

virtual only

Bag It educates, supports and empowers patients, caregivers & advocates. The Bag It Bag is the most respected and comprehensive resource for patient education. The Bag has a binder and resources to help patients organize medical records, cope with a diagnosis and advocate for their best quality of care. It includes publications and customizable tools designed to ensure your patients have access to current, credible information and tools to help them navigate their cancer journey.

Bladder Cancer Advocacy Network (BCAN)

Kiosk #A5

The Bladder Cancer Advocacy Network (BCAN) is a community of patients, caregivers, survivors, advocates, medical and research professionals united in support of people impacted by bladder cancer. Founded in 2005, BCAN is the only national advocacy organization devoted to advancing bladder cancer research and supporting those impacted by the disease. BCAN's mission is to increase public awareness about bladder cancer, advance bladder cancer research, and provide educational and support services for the bladder cancer community.

Visit bcan.org or email us at info@bcan.org to learn more about bladder cancer, find free resources, and/or sign up to receive our newsletter.

Cancer Support Community

virtual only

The Cancer Support Community is a global nonprofit that uplifts and strengthens people impacted by cancer. We are dedicated to fostering a community where people find connection, compassion, and knowledge. We provide professionally led support and navigation services, along with social connections and award-winning education—when, where, and how impacted individuals prefer throughout their cancer experience. We break down barriers to care through education, research, and advocacy. www.cancersupportcommunity.org

Cholangiocarcinoma Foundation

Kiosk #A11

Founded in 2006, the Cholangiocarcinoma Foundation is a global 501(c)(3) nonprofit organization. Its mission is to find a cure and improve the quality of life for cholangiocarcinoma patients. The Foundation is also part of a global alliance and partners with institutions in the United Kingdom, Thailand, Italy, Denmark, Japan, and other countries.

CLL Society

virtual only

CLL Society is an inclusive, patient-centric, physician-curated nonprofit organization that addresses the unmet needs of the chronic lymphocytic leukemia and small lymphocytic lymphoma (CLL/SLL) community through patient education, advocacy, support, and research. We explain the rapidly changing therapeutic landscape and the importance of clinical trials, build patient support networks, engage in research, and educate providers and patients. We believe SMART PATIENTS GET SMART CARE™. Learn more at cllsociety.org.

Crossroads4Hope

Kiosk #A9

Crossroads4Hope Mission: Crossroads4Hope's network embraces all people touched by cancer—the diagnosed and their loved ones—empowering individuals through access to resources, as well as programs of support, education, wellbeing, and hope.

Crossroads4Hope Services: We are experts in oncology and mental health, revolutionizing how we care for those facing cancer. Our services are at no cost to anyone and include professionally led individual and group support; education; distress screenings; nutrition and healthy cooking; health and wellness classes; and resources and referral. In addition to in-person and virtual programs, our digital platform, MyGo2Support, puts cancer support resources directly into patient's and family's hands via smartphone without having to download an app.

Patient Advocacy Pavilion

Global Colon Cancer Association **Kiosk #A1**

The Global Colon Cancer Association (GCCA) advocates for equitable access to quality colorectal cancer screenings, testing, treatments, and care, because where you live should not determine whether you can prevent or survive colorectal cancer. As both a membership-based umbrella organization and patient advocacy organization, GCCA amplifies and supports the efforts of our member organizations, develops adaptable advocacy and educational materials for our members, and conducts our own advocacy, education, and patient-centered policy initiatives.

Global Resource for Advancing Cancer Education (GRACE) **virtual only**

The Global Resource for Advancing Cancer Education (GRACE) provides expert-mediated information on current and emerging cancer management options in order to empower patients, caregivers, and health professionals to become direct partners in cancer care. cancergrace.org/

Founded in 2007 by Dr. Howard (Jack) West, GRACE democratizes cutting-edge cancer care by disseminating medical information through live/on-demand programs, webinars, podcasts, and written materials, aimed to educate patients and caregivers. GRACE fosters community engagement and knowledge sharing through their online forum, bridging the gap between medical professionals and patients. GRACE exemplifies breaking down barriers in cancer care, enhancing accessibility and understanding.

GO2 for Lung Cancer **Kiosk #A16**

GO2 for Lung Cancer transforms survivorship by working across the entire continuum of care for those who are at-risk or diagnosed with lung cancer.

Support services include:

- Helpline- 1:1 support by phone, email, and website
- LungMATCH- Treatment and trial navigation
- Phone Buddy Program- Peer matching support
- Lung Cancer Living Room Series- Expert speakers share about lung cancer topics
- Gathering Hope-monthly virtual social
- Online community through HealthUnlocked
- Free educational publications on a wide variety of topics

Head and Neck Cancer Alliance **Kiosk #A4**

Head and Neck Cancer Alliance strives to serve as a One-stop Center for patients, survivors, and family members seeking support and information about head and neck

cancer. From the management of symptoms to treatment options to clinical trials, HNCA works in partnership with medical and healthcare partners to provide up-to-date educational information, activities to promote awareness and education, and resources for patients to engage and learn from one another. We develop strategic priorities to tackle the challenges facing those impacted by this disease.

HealthTree Foundation **virtual only**

HealthTree is a nonprofit organization uniting patients and researchers through cutting-edge technology to work together on curing diseases. HealthTree provides lifetime personalized support and education to patients, meaningful patient-to-patient connections, and a powerful patient data portal, which transforms patients into active contributors of research that drives lifesaving breakthroughs. Visit healthtree.org

Imerman Angels **Kiosk #A8**

Imerman Angels' mission is To provide comfort and understanding for all cancer fighters, survivors, previvors and caregivers through a personalized, one-on-one connection with someone who has been there. Your one-on-one cancer community- so no one has to face cancer alone.

The Leukemia & Lymphoma Society **Kiosk #A3**

The Leukemia & Lymphoma Society (LLS) is the world's largest voluntary (nonprofit) health organization dedicated to funding blood cancer research, support, and advocacy. The LLS mission is to cure leukemia, lymphoma, Hodgkin's disease, and myeloma, and improve the quality of life of patients and their families. The mission is carried out through research, patient and professional education and services, and advocating for cures and access to care.

LLS provides free support, resources, and referrals, as well as virtual and local in-person education programs and videos to help all patients, survivors and their families stay informed about and access to the best possible treatment and follow-up care. LLS patient services include financial assistance, transportation and urgent need assistance, one-on-one peer-to-peer support, nutrition counseling, online chats and forums, and support groups. Services also include up-to-date disease and treatment information provided through the LLS website and printed booklets, as well as through one-on-one dialogue with Information Specialists and Clinical Trial Navigators in LLS's Information Resource Center (IRC) and the Clinical Trial Support Center (CTSC). The IRC and CTSC are on the front lines of LLS's efforts to improve patient access to quality care and to improve

Patient Advocacy Pavilion

patient quality of life. LLS also educates healthcare professionals about advancements in blood cancer research, treatment, side-effects management, resources for patients, and communicating with their patients about clinical trials. To access free CE/CME activities and resources visit www.LLS.org/CE.

LiveLung

Kiosk #A6

LiveLung is on a mission to improve health outcomes by advancing lung cancer education, early detection, and compassion for people impacted by lung cancer. We do this by hosting a network of monthly educational community lung cancer patient groups. We provide resource bags to dozens of cancer centers where nurse navigators give them to newly diagnosed lung cancer patients. We are a 501(c)(3) nonprofit organization, here to serve the lung cancer community.

The Myelodysplastic Syndromes Foundation Inc.

virtual only

The MDS Foundation is a global non-profit advocacy organization that for over 25 years has supported patients and their families as well as healthcare providers in the fields of MDS and its related diseases. The MDS Foundation supports and educates patients, their communities, and healthcare providers, and contributes to innovative research in the fields of MDS and its related continuum of diseases to better diagnose, control and ultimately cure these diseases.

Say YES to Hope

Kiosk #A13

Say YES to Hope is changing the world of advanced cancer through outreach, education, support, and hope. We are committed to serving these oft forgotten cancer patients as the association between access to care and support creates increased survival, better outcomes, and improved quality of life YES is a champion in the advanced cancer advocacy community. We are challenging you to join us and “bee the change” in the fight against advanced cancer!

Sharsheret

Kiosk #A10

Sharsheret is a national not-for-profit organization that supports women and families facing breast or ovarian cancer, or who are at higher diagnostic risk. Our free, confidential support includes access to social workers, a genetic counselor, and a range of programs, including financial subsidies, to help women navigate cancer diagnosis. Sharsheret has a wide array of educational brochures for you to share with patients and offers free professional training for your team (CE credit may be available). For more information or to order resources, visit us at www.sharsheret.org or call us at (866) 474-2274.

Tigerlily Foundation

Kiosk #A2

Tigerlily Foundation is one of the premier global organizations providing education, awareness, advocacy, empowerment and transformational programs to girls, young women, breast cancer survivors, metaversors, and caregivers – before, during and after breast cancer. Our programs impact young women of diverse ethnic backgrounds, underserved communities and those facing health disparities. Our programs also incorporate spirituality, holistic health, prevention, wellness, support, and survivorship programs to help you live your best life.

Tigerlily's ANGEL Advocacy Program provides comprehensive training for women of color between the ages of 21 – 50, who have been impacted by breast cancer. Contact us today to learn more!

Triage Cancer

Kiosk #A15

Triage Cancer is a national, nonprofit organization that provides free education on legal and practical issues that may impact individuals diagnosed with cancer and their caregivers, through events, materials, and resources.

Veterans Prostate Cancer Awareness

Kiosk #A7

Veterans Prostate Cancer Awareness (VPCa) is a nonprofit organization dedicated to promoting prostate awareness in the Veteran Population. The Goals and Mission of VPCa are to:

- Provide prostate cancer educational information and promote awareness among US Veteran population.
- Educate Veterans on screening, and available treatment options when faced with a prostate cancer diagnosis and empower Men to become their own Health Advocates.
- Promote new technologies for the treatment and cure of prostate cancer.

Young Adult Survivors United (YASU)

Kiosk #A12

Young Adult Survivors United (YASU) provides emotional, social, and financial support to young adult cancer patients & survivors aged 18-45 when diagnosed and their caregivers/co-survivors, enhancing their quality of life and hosting an age-appropriate community they need for peer support. Our virtual platform outreaches across the U.S. with in-person programming in Pittsburgh, PA where it is headquartered. Additional programs include free daylong or overnight respite trips, self-love workshops, and educational wellness seminars.

Did you know....

- Veterans are 40% more likely to develop Prostate Cancer?
- 15,000 new cases are diagnosed in the VHA System each year?
- There are over 500,000 Veterans in the VHA living with Prostate Cancer?
- You should screen early for prostate cancer if you are a Veteran?




Saving Veterans through Education, Awareness & Advocacy



Veterans Prostate
Cancer Awareness

www.VPCa.vet



**SIGN UP FOR OUR
NEWSLETTER**



WE CAN HELP!

RESOURCES FOR PATIENTS:

- Free educational webinars
- Annual Head & Neck Cancer Symposium
- Support services (mentors, online forum, nurse navigator)
- Gas card program


RESOURCES FOR MEDICAL PROFESSIONALS:

- Brochures for your office
- HNC screening kits
- Awareness Month press release templates, social media, and more



PARTNERS IN CARE FOR HEAD & NECK CANCER PATIENTS

 **LIBTAYO**[®]
(cemiplimab-rwlc)
Injection 350 mg



Patient portrayal

**Explore the clinical profile of LIBTAYO
across multiple indications**

**Visit Regeneron Booth 800 at NCCN
or [Libtayohcp.com](https://libtayohcp.com)**

April 5-7, 2024
Orlando World Center Marriott
Orlando, FL

[Click here to learn more](#)

REGENERON[®]

© 2023 Regeneron Pharmaceuticals, Inc. All rights reserved.
US.LIB.23.09.0017 09/23

Explore the clinical profile of LIBTAYO across multiple indications

To learn more scan here or visit LIBTAYOhcp.com



LIBTAYO[®]
(cemiplimab-rwlc)
Injection 350 mg

REGENERON[®]

Awareness. Education. Advocacy.

The Global Colon Cancer Association (GCCA) provides medically accurate patient educational materials about CRC biomarkers and their treatment impact, as well as patient stories and advocacy resources through our Know Your Biomarker program at knowyourbiomarker.org.

You can also find patient materials on CRC signs and symptoms, screening, prevention, and treatment on the GCCA website at globalcca.org/learn/colorectal-cancer.



Scan this QR code to receive our printed materials by mail. You can also download printable files on our website.



**GLOBAL
COLON CANCER
ASSOCIATION**

CONFRONTING LUNG CANCER STARTS HERE.

From the realization of risk to the moment of diagnosis, from finding care to staying informed and building your resources, we relentlessly advocate for all people at risk and living with lung cancer to confront the disease.

As your friends, your guides, your teachers, your advocates and your support system, GO2 is your go-to.

Learn more at go2.org.



Helpline: 1-800-298-2436



ANAL CANCER FOUNDATION

Our Resources for Patients

**Peer-to-peer support program
Side effect management resources
and more!**



Annual Summit



Webinar Series



Patient Guides

SPREAD THE WORD!

✉ info@analcancerfoundation.org

🌐 analcancerfoundation.org

CCF's Nursing Advisory Board

The Nursing Advisory Board (NAB) is comprised of nursing professionals (RN, MSN, DNP) with expertise in the management of patients with cholangiocarcinoma and who are currently practicing in cancer research centers throughout the United States.

MEMBERSHIP

Applications are accepted for review by NAB and CCF leadership. Membership may also be at the invitation of NAB leadership team. While there are no term limits, active participation is required for the following:

- Quarterly Meetings (virtual)
- Attendance at the Cholangiocarcinoma Foundation Annual Conference

PURPOSE

The NAB works collaboratively to generate and distribute education on various platforms that are specific to the treatment, care, and management of patient's with cholangiocarcinoma. In conjunction with the Medical Advisory Board and the CCF patient advocacy team, the NAB tailors material to the needs of patients, caregivers, and local healthcare professionals who are caring for patients with CCA and include but are not limited to the following:

- Clinical nursing practice guidelines
- CCF annual conference presentations/updates
- Patient/caregiver educational series through CCF webinars
- Abstract and poster presentations at national cancer conferences



**Cholangiocarcinoma
Foundation®**

for more information, please visit

curecca.org/nab



Tigerlily offers comprehensive programming across the continuum of breast health research, screening, prevention, and treatment to dismantle disparities and increase access to the care patients deserve.

We are committed to mobilizing our community of young women, caregivers, and loved ones to transform lives and recognize that we must Advocate Now to Grow, Empower & Lead through the **ANGEL Advocacy Program**.



The **Clinical Trials Program** is a transformational initiative to accelerate the delivery of innovative treatments to our patients with a strategic focus on populations that face the highest disparities.



To ensure patients and healthcare providers have the right resources at their fingertips to better equip patients and caregivers as they navigate a cancer diagnosis, download our **Barrier Toolkits**.



In partnership with WITT Forever, the **RAISE platform** makes it easy for patients to get resources and assistance for support and empowerment without feeling as though they are burdening others.



COME SEE US AT KIOSK A2!

Learn about these programs and more by visiting the Tigerlily website and following us on social media!

✉ info@tigerlilyfoundation.org

📷 [@tigerlily_foundation](https://www.instagram.com/tigerlily_foundation)

🐦 [@tigerlilycares](https://twitter.com/tigerlilycares)

📘 [@tigerlilyfoundation](https://www.facebook.com/tigerlilyfoundation)



“Triage Cancer...They fill a gap in support that makes life tangibly better for people with cancer and their families.”

TRIAGE CANCER®

Our mission:

Triage Cancer is a national, nonprofit organization that provides free education on the legal and practical issues that may impact individuals diagnosed with cancer and their caregivers, through events, materials, and resources.

Learn more at
[TriageCancer.org](https://www.TriageCancer.org)



We provide FREE resources for:

- Cancer Patients
- Caregivers
- Health Care Providers

On important topics:

- Insurance
- Work
- Finances
- Caregiving
- & More

If you or a loved one is interested in being connected with a **CAR T-cell therapy** navigator to learn about support and available resources - call or visit us online.



844-792-6517

[cancersupportcommunity.org/
car-t-navigation-referral](http://cancersupportcommunity.org/car-t-navigation-referral)

Brought to you by:



Stock Photo. Posed by Model.

**WE'RE HERE
TO HELP YOUR
PATIENTS.**



A blood cancer diagnosis can be overwhelming for your patients. Blood cancer patients, including those with leukemia, lymphoma, myeloma, myelodysplastic syndromes and myeloproliferative neoplasms can find hope, education, guidance and support from The Leukemia & Lymphoma Society (LLS).

Our Information Specialists complement the care you provide with FREE, in-depth personalized services that connect patients to financial assistance, patient education (including booklets, podcasts and webinars), online and in-person support, nutrition consultations and the LLS Clinical Trial Support Center for assistance with clinical trials.

Please contact us at **800.955.4572** or go to www.LLS.org/resources-healthcare-professionals.





We Are THE MDS FOUNDATION

Providing Professional Resources and Patient Support

MDS Foundation supports and educates patients, their communities, and healthcare providers, and contributes to innovative research in the fields of MDS and its related continuum of diseases to better diagnose, control and ultimately cure these diseases.



Centers of Excellence



Professional Learning Center



Professional Resources

- Podcasts
- Webinars
- International Congress
- Regional Symposia
- IPSS-R & IPSS-M Calculators



MDS Patient Resources

- Patient Podcasts
- Patient Webinars
- Patient Forums
- Free Resources on our website
- Referrals to our COEs

Scan the QR codes for additional information:



PROFESSIONAL MEMBERSHIP



MDSF HOME PAGE

www.mds-foundation.org




#MovetheMessage ▶



Join the Foundation for Women's Cancer to #MovetheMessage ▶

With this campaign, our goal is to increase awareness of gynecologic cancers, starting with historically marginalized communities, through dissemination of critical patient education resources.

Educational materials available for download @ MovetheMessage.org



About Us

We offer emotional, social, and financial support to enhancing the quality of lives for YA cancer survivors and their caregivers/co-survivors.



Because Young Adult Cancer is Different.

yasu
Young Adult Survivors United



Contact Us

724-719-2273

www.yasurvivors.org



Programs

- Virtual Supportive Chats
- Self-Love Workshops
- Financial Assistance
- Free Respite Trips
- Social Activities
- Educational Seminars
- Free Counseling (regional)
- Caregiver/Co-Survivor Support
- Hybrid Programming



BLING 4 CANCER

We offer volume discounts for non-profit groups & healthcare providers

Available online at www.normaleah.org



Necklaces



Earrings



Bracelets

Proceeds support life-saving cancer initiatives

Bling4Cancer is a collection of sparkling crystal beads, charms and awareness ribbons in 20 colors to correspond with all cancer and medical illness awareness colors. Choose from pre-designed items or create a custom made look! They're vibrant accessories that can fashionably honor someone who has been touched by cancer. Quantity discounts available.

Norma Leah
OVARIAN CANCER INITIATIVE

www.normaleah.org • normaleah@normaleah.org
309.794.0009 • 1612 Second Avenue • Rock Island IL • 61201





Global
Resource for
Advancing
Cancer
Education

Credible, Accessible, Patient Focused Cancer Education

The Global Resource for Advancing Cancer Education is a nonprofit organization developed out of a commitment to improve the care that cancer patients receive by teaching patients and their families about their cancer, and the best and most current treatments, across the globe.

Learn more about the patient education programs with GRACE! Follow us for more!



 @cancergrace.bsky.social
 cancergrace.org
 /cancerGRACE
 @cancerGRACE
 /GRACE4cancerinfo
 cancergrace

Visit us for more!

www.cancergrace.org



Your science
saves lives.

Telling its story
is an art.

We've been a trusted partner of the nation's top academic medical centers and comprehensive cancer centers for nearly 40 years.

STEEGETHOMSON.COM/CANCER

BRAND + STRATEGY
PR + VISIBILITY
PHILANTHROPIC
COMMUNICATIONS

Steege
Thomson

ASSOCIATION OF CANCER CARE CENTERS

Celebrating 50 years of innovation, education and advocacy and serving more than 40,000 members of the cancer care community



ASSOCIATION OF CANCER CARE CENTERS™



Scan the QR code
or visit acc-cancer.org
to learn more about ACCC.

Engage with Us Today!

- @ACCC
- @ACCCancer
- @acc_cancer
- @ACCCBuzz

Do You

KNOW



What You Need To

KNOW?

TRAININGS INCLUDE:

- The Impact of Culturally Competent Cancer Care
- Finding a New Normal: Helping Your Patients Manage Survivorship
- Hereditary Breast and Ovarian Cancers in the Jewish Community
- Coping with Cancer: A New Approach to Reduce Cancer-Related Stress in Patients

We can create additional trainings based on the specific needs of your health care team.

CONTACT US TO SCHEDULE A TRAINING!
MROSEN@SHARSHERET.ORG

SHARSHERET

WWW.SHARSHERET.ORG

General Poster Session I

Hosted by NCCN Oncology Research Program (ORP)

Session I Friday, April 5

Breakfast 7:30 - 8:30 AM | Morning Break 9:45 - 10:05 AM

Lunch 11:55 AM - 1:10 PM | Afternoon Break 3:15 - 3:35 PM

Follow the Expert Guided Poster Tour

Open to all attendees. No pre-registration required. Experts from NCCN Member Institutions will lead a group of conference attendees and highlight research. **Meet by the Posters in the Exhibit Hall at 12:25 PM.**

#	Presenting Author and Institution	Title	Co-Authors	Category
1	Chad Tang, MD <i>The University of Texas MD Anderson Cancer Center</i> NCCN Member Institution	Spatial Evolution of Immune Cell Dysfunction During Development of Oligometastatic Renal Cell Carcinoma: Secondary Analysis of a Prospective Trial	Kieko Hara, MD; Alexander D. Sherry, MD; Alejandra G. Serrano, MD; Larisa V. Kostousov, MS; Sharia D. Hernandez, MD; Wei Lu, MD, PhD; Li Shen, MS; Amishi Y. Shah, MD; Eric Jonasch, MD; Jose A. Karam, MD; Surena F. Matin, MD; Nizar Tannir, MD; Jing Wang, PhD; Pavlos Msaouel, MD, PhD; Kanishka Sircar, MD; Luisa Solis, MD	Clinical Oncology
2	Zachary A. K. Frosch, MD <i>Fox Chase Cancer Center</i> NCCN Member Institution	Patients' Perspectives on Being Treated by Multiple Care Teams for Autologous Transplant/CAR-T Eligible Lymphoma and Multiple Myeloma	Clark Meshack, MPH; Caitlin Meeker, MPH; Asya Varshavsky-Yanovsky, MD, PhD; Rashmi Khanal, MD; Michael Bromberg, MD, PhD; Ashwin Chandar, MD; Emmanuel Quien, MD; Jordan Carter, MD; Shazia K. Nakhoda, MD; Marcus Messmer, MD; Charissa Montgomery, MSN; Jason A. Incorvati, MD; Nadia D. Ali, MD; Michael J. Styler, MD; Carolyn Y. Fang, PhD	Outcomes and Health Services Research
3	Christos Fountzilas, MD <i>Roswell Park Comprehensive Cancer Center</i> NCCN Member Institution	A Phase I Study of TAS102 Plus Talazoparib in Advanced Colorectal (CRC) and Esophagogastric (EGC) Adenocarcinomas	Agnieszka Witkiewicz, MD; Sarah Chatley, BS; Victoria Fitzpatrick, DNP; Justin Zonneville, MS; Mohammed Alruwaili, MS; Hanna Rosenheck, MS; Donald Mager, PharmD, PhD; Jianxin Wang, PhD; Anuradha Krishnamurthy, MBBS; Benjamin Switzer, DO; Kristopher Attwood, PhD; Igor Puzanov, MD; Renuka Iyer, MD; Andrei Bakin, PhD	Clinical Oncology
4	Ana Tergas, MD, MPH <i>City of Hope National Medical Center</i> NCCN Member Institution	Genetic Ancestry and Genomic Alterations of Cervical Cancer in a Diverse Patient Population	Sara Byron, PhD; Guangfa Zhang, PhD; Tyler Izatt, MS; Jiaming Zhang, PhD; Nicholas Schork, PhD; Lorna Rodriguez, MD, PhD	Epidemiology/Risks/Prevention
5	Abhishek Chakraborty, PhD <i>Case Comprehensive Cancer Center/ University Hospitals Seidman Cancer Center and Cleveland Clinic Taussig Cancer Institute</i> NCCN Member Institution	The NF-κB Transcription Factor Is a HIF-Independent Oncogenic Dependency in Kidney Cancer	Shannon Zayas, MS; Treg Grubb, BS; Fengshen Kuo, PhD; Eduard Reznik, PhD; A. Ari Hakimi, MD; Abhishek Chakraborty, PhD	Pre-Clinical Oncology
6	Richard Tobin, PhD <i>University of Colorado Cancer Center</i> NCCN Member Institution	MAIT Cells are Reduced in Anorectal Mucosal Melanomas Compared to Cutaneous Melanoma GI Metastases	Elizabeth N. Katsnelson, BS; Kasey L. Couets, PhD; Andrea Spengler, BS; Liyen Loh, PhD; Laurent Gapin, PhD; Martin D. McCarter, MD	Correlative/Genomic
7	Shuang George Zhao, MD <i>University of Wisconsin Carbone Cancer Center</i> NCCN Member Institution	Liquid Biomarkers of Response to Radium-223 in Metastatic Prostate Cancer	Grace Blitzer, MD; Jamie Sperger, PhD; Menggang Yu, PhD; John Floberg, MD; Marina Sharifi, MD; Joshua Lang, MD	Correlative/Genomic
8	Lauren Laderman, MD <i>Fox Chase Cancer Center</i> NCCN Member Institution ORP-Funded Study	Does Routine Clinical Assessment of Older Adults with Gastroesophageal Cancer Tell the Whole Story?	Meghan Connors, BS; Caitlin R. Meeker, MPH; Elizabeth A. Handorf, PhD; Kelly A. Filchner, PhD; Mohamedtaki A. Tejani, MD; Grant R. Williams, MD, MSPH; Arthur Winer, MD; Sukeshi P. Arora, MD; Namrata Vijayvergia, MD; Efrat Dotan, MD	Outcomes and Health Services Research
9	Elham Nasrollahi, MD <i>UPMC Pinnacle Harrisburg</i>	Comparative Assessment of Social Determinants of Health in Community and Academic Hospitals for Patients Diagnosed with Hepatocellular Carcinoma	Adalberto Guzman, MD; Anas Atrash, MD	Outcomes and Health Services Research
10	Dena Berhan, BS <i>Moffitt Cancer Center</i> NCCN Member Institution	Implementation of an Integrated Supportive Care Medicine Consultation Service within a Gastrointestinal Cancer Clinic: Timeliness of Referrals and Patient Access	Nicole Nardella, MS, BS; Adrianna Oraiqat, BS; Denny Lu, HS; Sarah Goodchild, BS; Terry Gruchow, PA-C, MHS, DFAAPA; Young Chang, MD; Sahana Rajasekhara, MD; Pamela Hodul, MD	Outcomes and Health Services Research
11	Ujjwal Karki, MBBS <i>Corewell Health William Beaumont University Hospital</i>	Dynamic Changes in Circulating Tumor DNA Predicts Disease Progression or Regression in Colorectal Cancer	Bipin Ghimire, MBBS; Emma Trentacosta, MD; Mohammad Chisti, MD	Correlative/Genomic

General Poster Sessions | Session I | Friday, April 5 *continued*

#	Presenting Author and Institution	Title	Co-Authors	Category
12	Ericson John Torralba, BSc <i>Wright State University Boonshoft School of Medicine</i>	Microwave Ablation versus Resection versus Stereotactic Body Radiation Therapy of Stage IA Non-small Cell Lung Cancer in US Veterans	Garrett Fisher, BSc; Reid Fursmidt, MSc; Michael Gilbert, BSc; Perry Nystrom, MD; Albert Malcom, MD; John Mathis, MD; Robert Short, MD, PhD	Best Practices in Implementation and Use of Clinical Practice Guidelines
13	Jose Rivera, IIE, MBA <i>The University of Texas MD Anderson Cancer Center NCCN Member Institution</i>	A Safety Net System for Significant Diagnostic Imaging Actionable Findings at a Comprehensive Cancer Care Center	Carmen Gonzalez, MD; Tonita Bates, DNP, APRN	Quality Improvement
14	John Sharp, MD <i>The Ohio State University Comprehensive Cancer Center - James Cancer Hospital and Solove Research Institute NCCN Member Institution</i>	Immune Checkpoint Inhibitor-Induced Type 1 Diabetes Mellitus: Patient Characteristics, Clinical Outcomes, and Survival Implications of Autoantibodies	Cassandra Pasadyn, AB; Songzhu Zhao, MS; Lai Wei, PhD; Carolyn Presley, MD; Dwight Owen, MD, MS; Kathleen Wyne, MD, PhD; Alexa Meara, MD	Outcomes and Health Services Research
15	Mylinh Nam, BA <i>Kaiser Permanente Bernard J. Tyson School of Medicine</i>	Development of Heart Failure Following Anthracycline Exposure in Survivors of Adolescent and Young Adult Cancer in an Integrated Healthcare System	Mark Duggan, MA; Chun Chao, PhD; Robert Cooper, MD	Epidemiology/Risks/Prevention
16	Asim Waqas, PhD <i>Moffitt Cancer Center NCCN Member Institution</i>	Hierarchical Multimodal Learning on Pan-Squamous Cell Carcinomas for Improved Survival Outcomes	Aakash Tripathi, BS; Ashwin Mukund, MS; Paul Stewart, PhD; Mia Naeini, PhD; Ghulam Rasool, PhD	Bioinformatics/Information Technology Sciences
17	Cinzia Caparso, PhD <i>University of Michigan Rogel Cancer Center NCCN Member Institution</i>	"Share the Fear": Communication Concerns of Parents with Cancer with Dependent Children for their Co-parent: A Qualitative Study	Zoe Bowen, BS; Sung Won Choi, MSc, MD	Outcomes and Health Services Research
18	Tongmei Zhang <i>Beijing Chest Hospital</i>	Aneuploid Epcam + Disseminated Tumor cells (DTCs) Correlated with Liver Metastasis and Independently Predict Poor Survival in Small Cell Lung Cancer	Ying Wang; Hongxia Li; Baohua Lu; Yuan Gao; Yanxia Liu; Lina Zhang; Mingming Hu; Hongmei Zhang	Clinical Oncology
19	Sara Taveras Alam, MD <i>McGovern Medical School</i>	Real-World Outcomes in Patients with Burkitt Lymphoma in a Safety-Net Health System	Jun Y. Jiang, MD; Chijioke Nze, MD, MPH; Danielle Guffey, MS; Rockbum Kim, MD, PhD; Abiodun O. Oluyomi, PhD; Omar Rosales, MPH, BS; Raka Bandyo, MS; Courtney N. Miller-Chism, MD; Mark M. Udden, MD; Martha P. Mims, MD, PhD; Hilary Ma, MD; Gustavo A. Rivero, MD; Akiva Diamond, MD; Purnima S. Teegavarapu, MD; Christopher R. Flowers, MD, MS; Ang Li, MD, MS; Marie Lee, MD	Outcomes and Health Services Research
20	Abha Kulkarni, MD, MPH <i>New York-Presbyterian Weill Cornell Medical Center</i>	Surviving and Thriving After Lung Cancer: A Pilot Project to Understand Physician Perspectives on the Approach to Lung Cancer Survivorship Care at Weill Cornell Medicine Medical Oncology	Christine Garcia, MD, MPH	Quality Improvement
21	Nicole Nardella, MS, BS <i>Moffitt Cancer Center NCCN Member Institution</i>	Personalizing the Patient Experience: Understanding the Emotional State and Learning Preferences of Pancreatic Cancer Patients Receiving Multidisciplinary Care	Brian Gonzalez, PhD; Matt Adams, BS; Corinne Thomas, BS; Adrianna Oraiqat, BS; Maria Sandoval, MD; Jessica Frakes, MD; Russell Palm, MD; Carrie Stricker, MD; Joseph Herman, MD; Pamela Hodul, MD; Sarah Krüg, MS; Sarah Hoffe, MD	Outcomes and Health Services Research
22	Kashyap Patel, MD <i>Carolina Blood and Cancer Care Associates</i>	Real-World Clinical Benefit Among Patients (pts) with Lower-Risk Myelodysplastic Syndromes (LR-MDS) Treated with Luspatercept	Brandy Snyder, PharmD, MBA; Derek Tang, PhD, BSPHarm; Debanjana Chatterjee, PhD; Anupama Vasudevan, PhD, MPH; Uchechukwu Mordi, PharmD, MS; Harvey Katzen, MD; John Li, PhD, MPH; Lindsay Aton, MHA; Ali McBride, PharmD, MS	Outcomes and Health Services Research
23	Simi Aggarwal, PhD <i>Graticule Inc.</i>	Prior SARS-CoV-2 in Patients with CAR-T Negatively Impacts Overall Survival, Highlighting the Need for Targeted Prophylaxis Strategies	Andrew Ip, MD; Yuval Koren, MSc; Dan Poscover, MBA; Cátia Ferreira, PhD; Lisa Glasser, MD; Kathleen Heil, BSN; Della Varghese, PhD, MPH; Sudhir Venkatesan, MPH, PhD; Carla Talarico, PhD, MPH	Epidemiology/Risks/Prevention
24	Manu Prasad, MBA <i>ZS Associates</i>	Estimation of Impact of Care Gap on Patient Outcome and Healthcare Cost Burden Using Real World Data in Early Stage NSCLC- An Empirical Study for Delay in Surgery	Manu Prasad, MBA; Tianyuan Hu, MPH; Arunav Saikia, MS; Prabhakar Gaur, B. Tech; Venkata Sai Sumanth Pulluri, B.Tech; Stuti Jha, B. Tech	Best Practices in Implementation and Use of Clinical Practice Guidelines
25	Erin Comerford, MS <i>Sanofi-Aventis US LLC</i>	Patient-Reported Outcome (PRO) Data in Oncology NDAs Approved by the FDA (2018- 2021): A Review of Criticism and Concerns in Comments from Regulators	Lindsey Norcross, MA; Medha Sasane, PhD; Ying Zheng, MS, MHSA; Ari Gnanasakthy, MSc, MBA	Outcomes and Health Services Research
26	Atharv Sharma, BE <i>ZS Associates</i>	Impact of Social Determinants(SDOH) on Surgery and Patient Outcomes in Early-Stage Non-Small Cell Lung Cancer (eNSCLC)	Manu Prasad, MBA; Tianyuan Hu, MPH; Arunav Saikia, MS; Prabhakar Gaur, B. Tech; Venkata Sai Sumanth Pulluri, B. Tech; Stuti Jha, B. Tech	Best Practices in Implementation and Use of Clinical Practice Guidelines

General Poster Sessions | Session I | Friday, April 5 *continued*

#	Presenting Author and Institution	Title	Co-Authors	Category
27	Atulya Aman Khosla, MD Corewell Health William Beaumont University Hospital	Predicting Disparities in Adverse Dispositions Following Major Surgery for Lung Cancer Using Machine Learning	Vijval Rajan, BS; Mohammad Arfat Ganiyani, MD; Nitya Batra, MD; Karan Jatwani, MD; Rohit Singh, MD; Yanjia Zhang, PhD; Zhenwei Zhang, PhD, MD; Ashfaq Ahmed, PhD; Mukesh Roy, PhD; Venkataraghavan Ramamoorthy, MD, PhD; Muni Rubens, MD, PhD; Anshul Saxena, PhD; Aakash Desai, MD; Ishmael Jaiyesimi, MD	Bioinformatics/Information Technology Sciences
28	Sasmith Menakuru, MD Indiana University Melvin and Bren Simon Comprehensive Cancer Center NCCN Member Institution	Lung Cancer In Never Smokers: The Role of Radon Exposure and Public Knowledge	Vijaypal Dhillon, MD; Marriam Ali, MD; Ahmed Salih, MD; Nasser Hanna, MD	Epidemiology/Risks/Prevention
29	Vaishnavi Singh, MD Willis-Knighton Health System	Educational Efficacy of YouTube Videos on Multiple Myeloma	Shiva Jashwanth Gaddam, MD; Poornima Ramadas, MD; Samip Master, MD	Outcomes and Health Services Research
30	Shellie Ellis, MA, PhD University of Kansas School of Medicine	Development and Pilot Testing of a Comprehensive Set of Measures for Organizational Assessment of NCCN Guideline Recommended Genomic Testing	Aaron Katz, PharmD, PhD; Chao Huang, MD; Samuel Boyd, MS; Carolyn Caine, MA; Whitney Onasch, MBA; Daniel Farrell, MD, PhD; Jeffrey Thompson, PhD; Joaquina Baranda, MD; Rashna Madan, MD; Wei Zhang, MD; Zseraldina Ferenczi, MPA; Andrew K Godwin, PhD	Quality Improvement
31	Julie Wiedower Kaylor, PhDc, CGC Guardant Health Inc.	Utilization of Biomarker Testing and Biomarker-Driven Targeted Therapy Among Patients with Metastatic Non-small Cell Lung Cancer	Julie Wiedower Kaylor, PhDc, CGC; Karen M. Stockl, PharmD, MS; Jacqueline Lekostaj, MD, PhD; Jamie Tucker, MS; Shaun P. Forbes, PhD; Julia M. Certa, MPH; Caroline Weipert, MS, CGC; Keelia Clemens, PhD, MS, CGC; Lucy Langer, MD, MSHS	Outcomes and Health Services Research
32	Sangam Sangam, MD St. Barnabas Hospital	Mesothelioma: Trends in Palliative Care Utilization in Hospitalized Patients, a National Inpatient Sample (NIS) Study (2016-2020)	Marco Bermudez, MD; Francisco Gallegos Koyner, MD; Tripti Jain, MD; Shorabh Sharma, MD; Sorab Gupta, MD	Epidemiology/Risks/Prevention
33	Misbahuddin Syed, MD Moffitt Cancer Center NCCN Member Institution	Instituting Quality Improvement Processes with Periprocedural Heparin Infusions at a Major Cancer Center Utilizing a Failure Mode and Effects Analysis	James Lochner, CSSBB, MBA, MSQA; Katherine Helsel, MSN, RN, OCN; Misbahuddin Syed, MD, FACP	Quality Improvement
34	Jonathan C. Bastick, III, BS University of Louisville School of Medicine	High Dose Rate Interstitial Brachytherapy for Squamous Cell Carcinoma of the Vagina: Methods and Outcomes at a Single Institution	Andrés Portocarrero Bonifaz, MSc; Bryce Forry, BA; Maxwell Kassel, MSc; Salman Syed, MD; Grant W. McKenzie, MD; Keith T. Sowards, MSc; Jeremy T. Gaskins, PhD; Scott R. Silva, MD, PhD	Outcomes and Health Services Research
35	Diego Garmendia, BA Vanderbilt-Ingram Cancer Center NCCN Member Institution	Comparing Cancer Risk Management Between Females with Truncating CHEK2 1100delC versus Missense CHEK2 I157T Variants	Anne Weidner, MPH; Lindsay Venton, BSc; Tuya Pal, MD	Best Practices in Implementation and Use of Clinical Practice Guidelines
36	Adam Khorasanchi, MD The Ohio State University Comprehensive Cancer Center – James Cancer Hospital and Solove Research Institute NCCN Member Institution	Overall Survival (OS) Impact for NSCLC Patients with irAE and Non-irAE Hospital Admissions During First line Pembrolizumab Treatment	Songzhu Zhao, MS; Lai Wei, PhD; Mingjia Li, MD; Kevin Ho, MD; Hamzah Abu-Sbeih, MD; Evelyn Goodyear, BS; Austin Secor, BS; Peter Shields, MD; Kai He, MD, PhD; Jacob Kaufman, MD, PhD; Regan Memmott, MD, PhD; Asrar Alahmadi, MBBS; David Carbone, MD, PhD; Gregory Otterson, MD; Alexa Meara, MD; Carolyn Presley, MD; Dwight Owen, MD	Clinical Oncology
37	Janice DallaCosta, BSN, MBA Southcoast Health	Joining Forces to Minimize Hypomagnesemia in Patients Receiving Cisplatin and Cetuximab Infusions	Patrick Skeffington, PharmD, MHA, MSRA; Ny Tran, MSN	Quality Improvement
38	Keyi Jia, MD Tongji University Affiliated Shanghai Pulmonary Hospital	Combining Immunotherapy and Anti-angiogenesis Remodeling the Immune-microenvironment of LKB1/KEAP1-mutant Non-small Cell Lung Cancer	Shengxiang Ren, MD	Pre-Clinical Oncology
39	Vincent T. Ma, MD University of Wisconsin Carbone Cancer Center NCCN Member Institution	Microfluidic Characterization and Analysis of Circulating Tumor Cells from Patients with Metastatic Melanoma	Benjamin K. Gibbs, BS; Jennifer L. Schehr, PhD; Joshua M. Lang, MD, MS; Vincent T. Ma, MD	Correlative/Genomic
40	Chalothorn Wannaphut, MD John A. Burns School of Medicine	Pneumonitis Incidences in Metastatic Non-small Cell Lung Cancer on Immunotherapy: A Systematic Review and Meta-analysis.	Natchaya Polpichai, MD; Pharit Siladech, MD; Manasawee Tanariyakul, MD; Phuwadith Wattanachayakul, MD; Pakin Lalitnithi, MD	Clinical Oncology
41	Christine Vinci, PhD Moffitt Cancer Center NCCN Member Institution	A Mindfulness-based Intervention for Caregivers of Autologous Hematopoietic Stem Cell Transplant Patients: Pilot Study Results	Valerie V. Yepez, MMS; Sierra J. Washington, MPH; Sarah R. Jones, BA; L. Robert Gore, PhD; Sofia Fonseca, BA; Ranjita Poudel, PhD; Joseph Pidala, MD, PhD; Christine Vinci, PhD	Outcomes and Health Services Research

General Poster Sessions | Session I | Friday, April 5 *continued*

#	Presenting Author and Institution	Title	Co-Authors	Category
42	Priyal Agarwal, MD <i>Fred & Pamela Buffett Cancer Center</i> NCCN Member Institution	A National Cancer Data Base (NCDB) Analysis of Prognostic Factors in Metastatic Triple-Negative Breast Cancer (TNBC)	Amulya Yellala, MD; Samia Asif, MD; Valerie K. Shostrom, PhD; Meghana Kesireddy, MD	Clinical Oncology
43	Julia Olsen, MS <i>Hologic Inc.</i>	Disparities in Real-World Screening Mammography Compliance Rates by Body Mass Index and Mobility-Restricting Diagnosis – A Commercial Claims-Based Analysis	Scott Pohlman, MS; Jason Shames, MD	Outcomes and Health Services Research
44	Anuraag Kansal, PhD <i>Grail LLC</i>	Working and Cancer: The Impact of Cancer Diagnosis and Treatment on Employment, Presenteeism, and Productivity	Sarah A. Cohn, BS; Shelley Fuld Nasso, MPP; Elena M. Jeannotte, BA; Haley V. Smoot, MSc	Outcomes and Health Services Research
45	Daniel Simmons, PharmD, MS <i>Moffitt Cancer Center</i> NCCN Member Institution	Treatment Patterns in Surgically Resected NSCLC Since the Introduction of ImmunoOncology Agents	Daniel Simmons, PharmD, MS; Lu Zou, PhD; Yahan Zhang, MS; Wale Oyebanji, MD, MBA, MPH; Tiernan Mulrooney, PhD	Outcomes and Health Services Research
46	Anirudh Goyal, MD <i>University of Michigan</i> <i>Rogel Cancer Center</i> NCCN Member Institution	The Impact of the COVID-19 Pandemic on Cancer Treatments: A SEER Population Based Analysis	Oxana Crysler, MD	Outcomes and Health Services Research
47	Ming Lee, MD, PhD <i>Sylvester Comprehensive Cancer Center</i>	A Data-Driven Approach to Increase Lung Cancer Screening Rate in the Catchment Area of an NCI-Designated Cancer Center via Community Outreach and Engagement	Antonia Leavitt, MS; Alison Ramey, MS; Janelys Jones, MS; Javier Milan, MS; Lazara Pagan, MS; Chinmay Jani, MD; Gilberto Lopes, MD; Raymond Balise, PhD; Erin Kobetz, PhD	Epidemiology/Risks/Prevention
48	Sabeen Ahmed, PhD <i>Moffitt Cancer Center</i> NCCN Member Institution	Early Diagnosis of Cancer Cachexia Using Body Composition Index as the Radiographic Biomarker	Nathan Parker, PhD; Ghulam Rasool, PhD	Bioinformatics/Information Technology Sciences
49	Yukako Otani, MD, PhD <i>Dana-Farber/Brigham and Women's Cancer Center Mass General Cancer Center</i> NCCN Member Institution	Immune Cell Dynamics After Radiotherapy for Oligometastatic Prostate Cancer	Yukako Otani, MD; David Qi, BA; Isabella Rose Pompa, BA; Richard Kuo Dzung, PhD; Rea Pittie, BA; Ella Chung, BA; Keisuke Otani, MD, PhD; Jennifer Y. Wo, MD; Anthony L. Zietman, MD; Patrick M. Reeves, PhD; Eliezer M. Van Allen, MD; Jason A. Efstathiou, MD, DPHIL; David T. Miyamoto, MD, PhD	Pre-Clinical Oncology
50	Arvind Dasari, MD <i>The University of Texas</i> <i>MD Anderson Cancer Center</i> NCCN Member Institution	Efficacy of Fruquintinib in Less Heavily Pretreated Patients (Pts) With Metastatic Colorectal Cancer (mCRC): Profile-Matched Data From FRESCO and FRESCO-2	Cathy Eng, MD; Sara Lonardi, MD; Rocio Garcia-Carbonero, MD; Toshiki Masuishi, MD; Chiara Cremonini, MD; Francois Ghiringhelli, PhD; Joleen Hubbard, MD; Tarios Bekaii-Saab, MD; Jeremy Jones, MD; Rui-Hua Xu, MD; Lin Shen, MD; Jianming Xu, MD; Yuxian Bai, MD; Yanhong Deng, MD; Ying Yuan, MD; Wei Wei, PhD; Jianchang Lin, PhD; Lucy Chen, MD; Zhao Yang, PhD; William R. Schelman, MD; Shukui Qin, MD; Jin Li, MD	Clinical Oncology
51	Nishanth Thalambedu, MD <i>University of Arkansas for Medical Sciences</i>	Demographics and Outcomes of Autologous Stem Cell Transplant Among IgD Multiple Myeloma Patients	Phillip Farmer; Clyde Bailey; Lakshmi Yarlagadda, MD; Samer Al-Hadidi, MD, MS; Sharmilan Thanendrarajan, MD; Maurizio Zangari, MD; Carolina Schinke, MD; Frits VanRhee, MD, PhD	Clinical Oncology
52	Moazzam Shahzad, MD <i>Moffitt Cancer Center</i> NCCN Member Institution	Treatment Outcomes in VEXAS Syndrome in Patients with MDS: A Systematic Review	Muhammad Kashif Amin, MD; Muhammad Fareed Khalid, MD; Ahmad Basharat, MD; Jawad Noor, MD; Sakina Abbas, MD; Iqra Anwar, MBBS; Mohammad Aammad-Ud-Din, MD; Michael Jaglal, MD	Clinical Oncology
53	Xinghua Cheng <i>Shanghai Chest Hospital</i>	Single Cell Spatial Proteomics Reveals the Heterogeneity and Microenvironment Characteristics of Long-term Survival Patients of Small Cell Lung Cancer	Shun Lu, PhD; Xinghua Cheng, PhD, MD	Clinical Oncology
54	Puneeth Indurlal <i>McKesson Corporation</i>	Managing Pharmaceutical Costs in the Oncology Care Model	Christine Bates, MSN, RN; Cyndie Harrelson, BSN, RN; Kate Wallace, BSN, RN, OCN; Ann Sweeney; Meredith Jones, MS, BSN, BA; Karen Miller, BSN, RN; Marti Larriva, Pharm D; Susan Meyer, Pharm D; Tiffany Mitchem, Pharm D, CSP; Jody Agena, PharmD; Puneeth Indurlal	Quality Improvement
55	Yu-Cheng Chang, MD <i>Danbury Hospital</i>	The Impact of Proton Pump Inhibitors on Palbociclib in Advanced Breast Cancer Patients: A Systematic Review and Meta-analysis	Junmin Song, MD; Kuan-Yu Chi, MD; Pei-Chin Chen, MD, MSc; Aarushi Sudan, MD; Chin-Hsuan Huang, MD; Yu Chang, MD	Clinical Oncology
56	Gustavo Garcia, MD <i>Sarasota Memorial Hospital</i>	Red Cell Distribution Width and Putative Severity Markers as Predictors of Short-Term Critical Illness in Hospitalized Cancer Patients	Maha Hameed, MBBS; Kevin Cai Zhen, MD; Manuel Rosario, MD; Karen Hamad, MD; Wilhelmine Wiese-Rometsch, MD; Robert Smith, PhD	Clinical Oncology
57	Lynn Abbott-McCloud, MA <i>Dusty Joy Foundation/LiveLung</i>	Underserved Patients Find Their Voice Through Newly Formed SCLC Community	N/A	Outcomes and Health Services Research

General Poster Sessions | Session I | Friday, April 5 *continued*

#	Presenting Author and Institution	Title	Co-Authors	Category
58	Dominique Lopez, BS <i>Miami Cancer Institute</i>	Contemporary Treatment Patterns for Patients Diagnosed with cT1a Renal Tumors: A National Cancer Database Study	Aden Swayze, BA; Armin Ghomeshi, BS; Nathan VanderVeer-Harris, BS; Pushan Prabhakar, MBBS; Arjun Pon Avudaiappan, MS, MCh; Ahmed Eldefrawy, MD; Murugesan Manoharan, MD; Jorge Caso, MD; Dominique Lopez, BS	Clinical Oncology
59	Ellie Jhun, PharmD, PhD <i>OneOme, LLC</i>	Recommendation and Genotyping Discrepancies in DPYD for Oncology Patients	Jason D. Walker, PhD, HCLD (ABB); Ghada Elnashar, PharmD, MS; Julie Ceno-England, MD; Annmarie Hawe, MPGx; Cathryn Jennissen, PharmD, BCOP; Victor Tam, PharmD; James Kelley, MD, PhD	Correlative/Genomic
60	Yasunari Sakamoto, PhD, MD <i>International University of Health and Welfare Atami Hospital</i>	Compliance with Recommendations and Clinical Practices Increased After Publication of the Japanese Clinical Practice Guidelines for Pancreatic Cancer 2022 Edition	Takuji Okusaka, MD, PhD; Masahiro Yoshida, MD, PhD; Masafumi Nakamura, MD, PhD; Masayuki Kitano, MD; Yoshinori Ito, MD, PhD; Nobumasa Mizuno, MD, PhD; Keiji Hanada, MD, PhD; Masato Ozaka, MD; Chigusa Morizane, MD, PhD; Akiko Okumura; Toshio Fukuoka, MD; Yoshifumi Takeyama, MD, PhD	Quality Improvement
61	Christopher Armstrong, MS <i>University of Miami Miller School of Medicine</i>	Sociodemographic Trends and Regional Disparities Associated with Leukemia in Florida: Implications of an Aging-Population on Leukemia Incidences and Mortalities in the United States	Rebecca Kaiser, BS; Christopher Armstrong, MS; Nancy Elliott, PhD; Justin Taylor, MD; Raymond Balise, PhD; Erin Kobetz, PhD	Epidemiology/Risks/Prevention
62	Samantha Schimmel, BA <i>University of South Florida Morsani College of Medicine</i>	Prolonged Anesthesia as a Risk Factor for Extended Length of Stay Following Craniotomy for Primary Glioma	Jonah Gordon, BS; Adam Alayli, BS; Gavin Lockard, BS; Anshruta Dhanashekar, BS; Vishnu V. Iyer, BS; Bassel El Sayed, BS; Samuel Bauserman, BS; Nasrin Aldawoodi, MD; Allan Escher, DO; Rahul Mhaskar, MPH, PhD; Nam D. Tran, MD, PhD	Clinical Oncology
63	Maya Gogtay, MBBS, MD <i>Fred & Pamela Buffett Cancer Center NCCN Member Institution</i>	Does Immunotherapy Work in Patients With Poor Performance Status?	Omar Khaled Abughanimeh, MBBS; Benjamin A. Teply, MD	Outcomes and Health Services Research
64	Mary Stanley, LMSW <i>Association of Community Cancer Centers</i>	Optimizing the Implementation of New Therapies in Multiple Myeloma	Craig Emmitt Cole, MD; David Vesole, MD, PhD; Mary Stanley, LMSW; Kimberly Demirhan, MBA, BSN, RN; Latha Shivakumar, PhD; Elana Plotkin, BS	Best Practices in Implementation and Use of Clinical Practice Guidelines
65	Jennifer MacDonald, PharmD, BCOP <i>Medical University of South Carolina</i>	Institutional Policy Implementation for Allocating Chemotherapy During a Shortage	Carrie Hertzke, MBA, MD; Kelly Gaffney, PharmD, BCOP; Kristie Fleming, PharmD; Albert Craig Lockhart, MD; Carolyn Ann Gentles, DNP, FNP-C; Joshua Arenth, MD; Laura Sample, MHA, FACHE; Shelly Ozark, MD, HEC-C; Michelle Hudspeth, MD; Grant Goodrich, PhD	Best Practices in Implementation and Use of Clinical Practice Guidelines
66	Pushan Prabhakar, MBBS <i>Miami Cancer Institute</i>	Impact of Neoadjuvant Chemotherapy on Survival and Pathological Response Among Octogenarians who underwent Radical Cystectomy for Muscle-Invasive Bladder Cancer	Pushan Prabhakar, MBBS; Ahmed Eldefrawy, MD; Jorge Caso, MD; Murugesan Manoharan, MD	Clinical Oncology
67	Sreevalli Anantharamu, MBBS, MD, DM <i>Kidwai Memorial Institute of Oncology</i>	Induction Chemotherapy in Locally Advanced Squamous Cell Carcinoma of Head and Neck- Biweekly Docetaxel, Cisplatin, 5-fluorouracil, Leucovorin (TPFL) versus Triweekly TPF: Response Assessment and Translation into Survival Benefit	Sreevalli A.; L.A. Jacob, DM; L. Dasappa, DM; M.C. Suresh Babu, DM; Iokesh K. N., DM; A. Rudresha, DM; R. Lakkavalli Krishnappa, DM; S. Saldanha, DM	Clinical Oncology
68	Ruixuan Jiang, PharmD, PhD <i>Merck & Co Inc.</i>	Real-World Clinical Outcomes of First-Line Therapies and Treatment Regimens for BRAF-Mutant Advanced/Metastatic Melanoma: Retrospective Observational Study	Geoffrey Johnson, PhD; Emilie Scherrer, MSc; John Kang, PhD; Kathleen M. Aguilar, MPH, PhD; Rohini Singh, MPH, MD; Eric D. Whitman, MD	Outcomes and Health Services Research
69	Jingbo Yu, MD, PhD <i>Incyte Corporation</i>	Treatment Patterns and Blood Count Control in 10,112 Patients With Polycythemia Vera Managed at Community Practices in the United States	Anupama Vasudevan, BDS, MPH, PhD; Harvey Katzen, MD; Evan Braunstein, MD, PhD	Outcomes and Health Services Research
70	Carina Hernandez, MD, PhD <i>SUNY Upstate Medical University Hospital</i>	A Rare Case of Extranodal Primary Gallbladder Lymphoma Presented as Biliary Obstruction and treated with Rituximab and Lenalidomide	N/A	Clinical Oncology
71	Jason Alter, PhD <i>Exosome Diagnostics</i>	Utilization of ExoDx Prostate Test for Prostate Cancer Risk Stratification in the African American Population	Ronald Tutrone, MD; Christian J. Ray, PhD; Sonia Kumar, PhD; Grannum Sant, MD; Yiyuan Yao, MS; Vinita Verma, MPH; Johan Skog, PhD	Best Practices in Implementation and Use of Clinical Practice Guidelines

General Poster Sessions | Session I | Friday, April 5 *continued*

#	Presenting Author and Institution	Title	Co-Authors	Category
72	Zena Chahine, MD <i>University of Kentucky Markey Cancer Center</i>	A Comparison of Somatic Mutations and ELN Classification in De Novo Acute Myeloid Leukemia Between Appalachian and Non-Appalachian Kentucky	Xitong Zhou, PhD; Anna Johnson, DO; Trevor Morris, MD; Ashley Soule, PharmD; Hifsa Taj, MBBS; Claire McAvoy, PharmD; Chaitanya Iragavarapu, MD; Reinhold Munker, MD; Gregory Monohan, MD; Fevzi Yalniz, MD; Ayman Qasrawi, MD; Reshma Ramlal, MD	Epidemiology/Risks/Prevention
73	Carla Patel, DNP <i>The University of Texas MD Anderson Cancer Center</i> NCCN Member Institution	Pumping Iron in the Preoperative Period: Is It Beneficial in Reducing Blood Transfusions?	Danielle Fournier, DNP, APRN, AGPCNP-BC; Susan Knippel, DNP, APRN, FNP-C; Cheryl Fraser, MSN, APRN, ACNP-BC; TaCharra Laury, DNP, APRN, ACNP-BC; Hue Cao, MS, PA-C; Mini George, DNP, APRN, FNP-BC; Arlene Correa, PhD; Amber Aktar, PA-C	Best Practices in Implementation and Use of Clinical Practice Guidelines
74	Broc Kelley, BS <i>University of Wisconsin Carbone Cancer Center</i> NCCN Member Institution	Rectal Cancer Disparities in Age and Overall Survival Among American Indian and Alaska Native vs Non-Hispanic White Populations	Margaret R Walker, MD, MPH; John M Hampton, MS; Syed Nabeel Zafar, MD, MPH; Cibebe B Carroll, MD, MPH, PhD; Dana Hayden, MD, MPH, FACS, FASCRS; Andrea Schiefelbein, MSPH; Bret Benally Thompson, MD; Noelle K LoConte, MD, FASCO	Outcomes and Health Services Research
75	Grant Andres, RN <i>Arizona Oncology Associates PC</i>	Technology's Impact on Implementing the NCCN Distress Thermometer in a Community-based Oncology Clinic	Kelly Huey, MSW, LCSW; Lorraine Lopez, BSN RN; Christine Bates, MSN, RN, CMHP; Maria Acosta, CMA; Cyndie Harrelson, BSN RN; Donald Brooks, MD	Quality Improvement
76	Rachel Mea, MSN, RN Jillian K. Tuzio, MSN, RN, AGCNS-BC, OCN <i>Abramson Cancer Center at the University of Pennsylvania</i> NCCN Member Institution	Implementation of an USG Peripheral IV Placement Program	N/A	Quality Improvement
77	Chalothorn Wannaphut, MD <i>John A. Burns School of Medicine</i>	Organomegalies as a Predictive Indicator of Leukemia Cutis in the Patients with Acute Myeloid Leukemia	Chanakarn Kanitthamniyom, MD; Penvadee Pattanaprichakul, MD; Smith Kungwankiatichai, MD; Weerapat Owattanapanich, MD	Clinical Oncology
78	Chi-Yin Liao, PhD <i>Eli Lilly and Company</i>	Real-world Treatment Patterns and Effectiveness of Selpercatinib in Patients with Locally Advanced/metastatic Non-small Cell Lung Cancer in the US	Carmen Gonzalez-Ferrer, MSc; Samuel Whipple, PhD; Naleen Raj Bhandari, PhD; Patrick M. Peterson, PhD; Scott S. Barker, PhD; Feng Wang, PhD	Outcomes and Health Services Research
79	Teresa Pardo, MSc <i>Fundación ECO</i>	Molecular Tumor Boards Excellence. Phase 1 - State of the Art in Spain	Beatriz Belosillo, MD, PhD; Miguel Ángel Calleja, PhD; Jesús García-Foncillas, MD, PhD; Fernando López-Ríos, MD, PhD; Laura Mezquita, MD, PhD; Luis Paz-Ares, MD, PhD; Pedro Pérez Segura, MD, PhD; José Luis Rodríguez Peralto, MD, PhD; Xavier Solé, PhD; Ruth Vera, MD, PhD; Ana Vivancos, MD, PhD; Paula Gratal, PhD; Teresa Pardo, MSc; Alvaro Rogado, MBA; Carlos Camps, MD, PhD	Quality Improvement
80	Ahmed Abdelhakeem, MD <i>Baptist Hospitals of Southeast Texas</i>	Impact of Socioeconomic Status on Cancer Care in Southeast Texas: A Population-based Cohort Study	Jacob Thompson, MS; Junaid Anwar, MD; Telice Terro, RN, OCN; Maryam Vasefi, PhD	Outcomes and Health Services Research
81	Brooke Leon, BA <i>Cardinal Health Inc</i>	Community Oncologists' Perceptions on the Evolving Role of Surrogate Endpoints in Oncologic Clinical Trials	Robert N. Bone, PhD; Yolaine Jeune-Smith, PhD; Bruce Feinberg, DO	Outcomes and Health Services Research
82	Arjun Pon Avudaiappan, MD <i>Miami Cancer Institute</i>	Evaluation of the Reliability of mpMRI in Diagnosing Prostate Cancer Following Intravesical Bacillus Calmette Guerin Therapy for Bladder Cancer	Pushan Prabhakar, MD; Surya Chundru, MD; Andrew Renshaw, MD; Ahmed Eldefrawy, MD; Jorge Caso, MD; Murugesan Manoharan, MD	Clinical Oncology
83	Marina Aweeda, BS <i>Vanderbilt-Ingram Cancer Center</i> NCCN Member Institution	Reimagining the Pathology Report: Virtual 3D Specimen Mapping in Oncologic Surgery	Carly Fassler, BS; Yuna Chung, HS; Liyu Huang, HS; Spencer Yueh, BS; Joshua M. Lawrenz, MD; James S. Lewis, MD; Michael C. Topf, MD	Quality Improvement
84	David Wei, PhD <i>Novartis Pharmaceuticals Corporation</i>	Patient-Reported Outcome Measures Used In Patients With Chronic Phase-Chronic Myeloid Leukemia: A Systematic Review Of The Literature	Lovneet Saini; Aditi Kataria; Kejal Jadhav, MS Daisy Yang, PharmD; David Wei, PhD	Outcomes and Health Services Research
85	Cesar Simbaqueba Clavijo, MD, MPH <i>The University of Texas MD Anderson Cancer Center</i> NCCN Member Institution	Cemiplimab Use in Advanced Cutaneous Squamous Cell Carcinoma and Non-small Cell Lung Cancer - Risk Factors Associated with Mortality	Mehmet Altan, MD; Maria Franco-Vega, MD; Melvin Rivera, PharmD; Anisha Patel, MD	Clinical Oncology
86	Ayobami Olafimihan, MD <i>John H. Stroger Jr. Hospital of Cook County</i>	Disparities in Colorectal Cancer Mortality Outcomes: A Ten Year Trend Study	Inimfon Jackson, MD, MPH, PhD; Stanley Ozogbo, MD, MPH; Jeremiah Bello, MD; Praise Fawehinmi, BSc; Hafeez Shaka, MD; Michael Mullane, MD	Epidemiology/Risks/Prevention
87	Teresa Pardo, BSc, MSc <i>Fundacion ECO</i>	Quality Recommendations for the Management of Cutaneous Squamous Cell Carcinoma (CSCC)	Javier Cañueto Álvarez, MD, PhD; Josep Oriol Bermejo Segú, MD, PhD; Almudena García Castaño García Castaño, MD, PhD; Vanessa Gabriela Jerviz Guía, MD, PhD; Ana María López López, MD, PhD; Susana Puig Sardá, MD, PhD; Onofre Sanmartín Jiménez, MD, PhD; Ainara Soria Rivas, MD, PhD; Paula Gratal, PhD; Teresa Pardo, MSc; Alvaro Rogado, MBA; Alfonso Berrocal, MD, PhD	Best Practices in Implementation and Use of Clinical Practice Guidelines

General Poster Sessions | Session I | Saturday, April 5 *continued*

#	Presenting Author and Institution	Title	Co-Authors	Category
88	Arjuhn R., MD Madras Medical College and Research Institute: Madras Medical College and Government General Hospital	Hippocampal Optimization and Dosimetric Analysis on Feasibility of Hippocampal Sparing in Primary Gliomas- A Retrospective Dosimetric Study in a Tertiary Care Centre	Jeeva S., MBBS, MDRT; Vijayasree T. N., MBBS, MDRT	Clinical Oncology
89	Rose Chang, ScD Merck & Co Inc.	Real-world Treatment Patterns of Selumetinib Among Patients with Neurofibromatosis Type I and Plexiform Neurofibroma in the United States	Rose Chang, ScD; Theresa Dettling, MPH; Raj Desai, PhD; Chi Gao, ScD; Azeem Banatwala, BS; Sydney Ng, MPH; Sama Ahsan, MD; Mei Sheng Duh, ScD	Outcomes and Health Services Research
90	Shyamala Navada, MD Geron Corporation	Relationship Between Durable Transfusion Independence (TI) and Survival Outcomes in Patients (Pts) With Lower-Risk Myelodysplastic Syndrome (LR-MDS): An Analysis From US Health Insurance Claims Data	Nishan Sengupta, PhD; Dylan Supina, PhD; Shyamala Navada, MD; Ravi Potluri, B. Tech; Rohit Tyagi, MPH; Timothy Werwath, MS; Zhouer Xie, MD; Eric Padron, MD; David Sallman, MD	Outcomes and Health Services Research
91	Junaid Anwar, MD Baptist Hospitals of Southeast Texas	Efficacy of Selinexor in Acute Myeloid Leukemia: A Systematic Review and Metanalysis	Muhammad Haseeb, MD; Anusha Baddam, MBBS; Salma Saidahmed, MBBS; Binayak Singh, MBBS; Roshan NA, MBBS; Zahoor Ahmed, MBBS; Ahmed Abdelhakeem, MD; Kachhadia Meet, MBBS; Raza Zarrar, MD; Tahir Naqvi, MD	Clinical Oncology
92	Brenda Santellano, MD Augusta University	The Role of Social Determinants of Health in Gastrointestinal Cancer Outcomes in the United States Context: A Systematic Review	Rashi Agrawal, MS; Gabriela Duchesne, MS; Muhannad Sharara, MD; E. Andrew Balas, MD, PhD; Gagan Agrawal, PhD; Meng-Han Tsai, PhD; Asha Nayak-Kapoor, MD; Jorge E. Cortes, MD	Epidemiology/Risks/Prevention
93	Jessica Neeb, MSN, RN, OCN The US Oncology Network	Place of Death from Cancer in Episodic Value Based Care Models in a Community Oncology Network	Lalan Wilfong, MD; Sharon Hart, CMHP; Hope Ives, BS; Jessica Neeb, MSN, RN, OCN	Quality Improvement
94	Amanda Watson, BHSc Lymphoma Coalition	Predicting Treatment Related Fatigue in the Context of Lymphoma and Chronic Lymphocytic Leukemia	Amanda Watson, BHSc; Shawn Sajkowski, BA; Natacha Bolaños; Lorna Warwick, BA	Outcomes and Health Services Research
95	Sierra Washington, MPH Moffitt Cancer Center NCCN Member Institution	Efficacy of a Mindfulness-Based Stress Management Program for Allogeneic HCT Caregivers: Trial in Progress	Sofia Fonseca, BA; Valerie Yopez, MMS; Karen Brandon, PhD; Bob Gore, PhD; Min-Jang Yang, PhD; Sarah Jones, BA; Ranjita Poudel, PhD; Maija Reblin, PhD; Heather Jim, PhD; Joseph Pidala, MD, PhD; Christine Vinci, PhD	Trials in Progress
96	Rima Nakrani, MD, MSc Fox Chase Cancer Center NCCN Member Institution	A Multi-Center Phase I Trial of Neratinib and Fam-Trastuzumab Deruxetecan in Advanced Refractory Gastric Cancer Patients	Tanu Singh, MS, PhD; Elizabeth Handorf, PhD; Katherine R. Alpaugh, PhD; Namrata Vijayvergia, MD	Trials in Progress
97	Norman LaFrance, MD PLUS Therapeutics	Rhenium (RE-186) Obisbameda (RE-186 nanoliposome (186RNL)) in Leptomeningeal Metastasis [LM] Phase 1/2A Dose Escalation Trial: Update of Initial Safety and Feasibility Through Cohorts 1-4	Andrew Brenner, MD; Priya Kumthekar, MD; Michael Youssef, MD; Ande Bao, PhD; Melissa Moore, PhD; Joel Michalek, PhD; Marc Hedrick, MD; William Phillips, MD; Toral Patel, MD; Jeffrey Weinberg, MD; John Floyd, MD	Trials in Progress
98	Airat Garifullin, MD P. A. Herzen Moscow Research Oncology Institute	Revolutionizing NO Therapy: Novel NO Generator Enhances Quality of Life and Cardiopulmonary Function in Lung Cancer Patients	Peter Shegay, Dr; Oleg Aleksandrov, Dr; Oleg Pikin, Dr; Andrey Ryabov, Dr; Airat Garifullin, MD	Trials in Progress
99	Vandana Dhingra, DNB All India Institute of Medical Sciences - Rishikesh	Role of [99m Tc] DTPA-bis(Choline) in Evaluation of Breast Cancer: A Prospective Diagnostic Trial in Progress at AIIMS Rishikesh	Vandana Dhingra, DNB; Puja P. Hazari, PhD; Shranav Jha, MD; Sanjith LS, MD	Trials in Progress

General Poster Session II

Hosted by NCCN Oncology Research Program (ORP)

Session II Saturday, April 6

Breakfast 7:30 - 8:30 AM | Morning Break 9:45 - 10:05 AM

Lunch 11:55 AM - 1:10 PM | Afternoon Break 3:00 - 3:30 PM

Follow the Expert Guided Poster Tour

Open to all attendees. No pre-registration required. Experts from NCCN Member Institutions will lead a group of conference attendees and highlight research. **Meet by the Posters in the Exhibit Hall at 12:25 PM.**

#	Presenting Author and Institution	Title	Co-Authors	Category
100	Adrianna Oraiqat, BS Moffitt Cancer Center NCCN Member Institution	Improved Access through an Integrated Supportive Care Model Reduced Urgent Care Referral and Admission Rates for Patients with Gastrointestinal Malignancy	Nicole Nardella, MS, BS; Dena Berhan, BS; Denny Lu, HS; Sarah Goodchild, BS; Terry Gruchow, PA-C, MHS, DFAAPA; Young Chang, MD; Sahana Rajasekhara, MD; Pamela Hodul, MD	Outcomes and Health Services Research
101	Alexandrina Balanean, MPH Cardinal Health Inc	Comparing Apples to Apples in Uterine Cancer: Racial Disparity and Propensity Score Matching	Yolaine Jeune-Smith, PhD; Parisa Asgarisabet, PhD; Camryn Craig, BS; Harlen Hays, MPH; JaLyna Laney, RN; Ajeet Gajra, MD, MBBS, FACP; Bruce Feinberg, DO	Outcomes and Health Services Research
102	Danielle Brabender, MD University of Southern California Keck School of Medicine	The Clinical Effect of a Community-Based Genetic Testing Program	Emily Siegel, MD; Julie Culver, MS; Jacob Comeaux, MS; Anjali Date, MD; Amanda Woodworth, MD	Epidemiology/Risks/Prevention
103	Yazan Madanat, MD UT Southwestern Simmons Comprehensive Cancer Center NCCN Member Institution	Results From Phase 3 Trial of Imetelstat, a First-in-Class Telomerase Inhibitor, in Patients With Red Blood Cell Transfusion Dependent (RBC-TD) Non-del(5q) Lower Risk Myelodysplastic Syndromes (LR-MDS) Relapsed/Refractory to/Ineligible for Erythropoiesis Stimulating Agents (ESAs)	Michael R. Savona, MD; Mikkael A. Sekeres, MD; Uwe Platzbecker, MD; Valeria Santini, MD; Pierre Fenaux, MD, PhD; Maria Diez-Campelo, MD, PhD; David Valcárcel, MD, PhD; Tymara Berry, MD; Souria Dougherty, MBA; Sheetal Shah, BA; Libo Sun, PhD; Ying Wan, MD, PhD; Fei Huang, PhD; Shyamala Navada, MD; Rami S. Komrokji, MD; Amer M. Zeidan, MBBS, MHS	Clinical Oncology
104	Xiaohan Hu, PhD, MPH Merck & Co Inc	Biomarker Testing, Surgical Outcomes, and Adjuvant Therapy Rates Among Patients with Resected Non-Small Cell Lung Cancer (NSCLC) in the Community Setting in the United States (US), 2019–2023	Yu-Han Kao, PhD; Ashwini Arunachalam, MPH, BDS; Diana Chirovsky, PhD; Yiru Wang, PhD; Chenan Zhang, MS, PhD; Kaitlyn Kane, MS; Ayman Samkari, MD	Outcomes and Health Services Research
105	Derek W. Ren, BS UCLA Jonsson Comprehensive Cancer Center NCCN Member Institution	Improving Anal Cancer Screening: A Comparative Analysis of High-Risk Human Papillomavirus Tests, Alone or in Combination with Anal Cytology Assays, to Predict High-Grade Squamous Intraepithelial Lesions	Hilary K. Hsu, PhD; Jenny Brook, MS; Gypsyamber D'Souza, PhD; Jian Yu Rao, MD; Todd Brown, MD; Matt Moran, MSN, ANP-BC; Frank J. Jenkins, PhD; Ernesto Rodriguez, MSN; David Elashoff, PhD; Stephen Young, PhD; Nancy Joste, MD; Robert K. Bolan, MD; Seongmeen Kim, BSN; Susheel Reddy, MPH; Elizabeth Chiao, MD, MPH; Elizabeth Stier, MD; Dorothy Wiley, PhD	Epidemiology/Risks/Prevention
106	Nitya Batra, MBBS Corewell Health William Beaumont University Hospital	Myeloid Sarcoma in a Patient with Marfan Syndrome	Atulya Aman Khosla, MBBS; Shyam Poudel, MD; Daniel Ezekwudo, MD, PhD	Clinical Oncology
107	Guy Shechter, PhD, MBA MedTech Analytics, LLC	Autonomic Symptoms May Suggest Paraneoplastic Neurological Syndromes in Small Cell Lung Cancer	David Morrell, MBA; Regina Grebla, PhD; Steven Vernino, MD, PhD	Outcomes and Health Services Research
108	Caitlin Finelli, DO South Pointe Hospital	Evaluating and Improving Post-Operative VTE Prophylaxis in Patients with a History of Cancer: Results of a Quality Improvement Initiative in a Community Hospital Setting	Kristen Conrad-Schnetzer, DO; Tasha Bandiera, MSSA, LISW-S, AMC-SW	Best Practices in Implementation and Use of Clinical Practice Guidelines
109	Thakshila Liyanage, PhD Early Is Good, Inc.	A Cost Effective, Noninvasive Multiomics Assay (BCDx) for Diagnostic Accuracy of Bladder Cancer Compares to the Gold Standard of Cytoscopy and Cytology	Asel Habarakada Liyanage, MSc	Quality Improvement
110	Keisuke Otani, MD, PhD Dana-Farber/Brigham and Women's Cancer Center Mass General Cancer Center NCCN Member Institution	Impact of Somatic Mutations on Outcomes of Salvage Radiation and Hormonal Therapy for Prostate Cancer Recurrence After Prostatectomy	David J. Konieczkowski, MD, PhD; Daniel J. Rodden, BA; Shulin Wu, MD; Elai Davicioni, PhD; Philip J. Saylor, MD; Douglas M. Dahl, MD; Chin-Lee Wu, MD, PhD; Sophia C. Kamran, MD; Jason A. Efstathiou, MD, PhD; David T. Miyamoto, MD, PhD	Correlative/Genomic
111	Xiaohui Chen, MD, PhD First Affiliated Hospital of Fujian Medical University	Epigenetic Analysis on RUNX3 Mislocalization and its Association with Tumor Microenvironment Alteration in Non-small Cell Lung Cancer	Chuangzhong Huang, PhD; Yi Shi, PhD; Jianping Lu, MD; Xinlong Zheng, MD; Weifeng Zhu, MD; Yibin Cai, MD; Weibin Liu, MD	Correlative/Genomic

General Poster Sessions | Session II | Saturday, April 6 *continued*

#	Presenting Author and Institution	Title	Co-Authors	Category
112	Carly McCain, BS, BSN <i>Northside Hospital Atlanta</i>	Reporting the False Negative Rate of Sentinel Lymph Node Biopsy for Melanoma. SLNB: a Useful Quality Control Metric	Janice Bone, BS; Mildred Jones, BA; Nicole Kounalakis, MD	Best Practices in Implementation and Use of Clinical Practice Guidelines
113	Amy F. Ballou, DNP <i>University of South Carolina</i>	Characteristics of Individuals with Early-Onset GI Cancers in the Southeastern US	Abbas S. Tavakoli, DrPH, MPH, ME; Karen E. Wickersham, PhD, RN	Epidemiology/Risks/Prevention
114	Brooke Dulka, PhD <i>Cardinal Health Inc.</i>	Perceptions of CARTITUDE-4 for Patients With Relapsed/Refractory Multiple Myeloma	Luke Jennings-Zhang, PharmD; Samuel Baird, MPH; Robert N. Bone, PhD; Yolaine Jeune-Smith, PhD; Muhamed Baljević, MD; Bruce Feinberg, DO	Outcomes and Health Services Research
115	Yasmine Katzmann <i>Watson Clinic LLP</i>	Monitoring Concordance of Chronic Lymphocytic Leukemia (CLL) at Watson Clinic LLP: Diagnosis & Treatment	Shalini Mulaparthy, MD; Noreen McGowan, RN, BSN, CCRC	Quality Improvement
116	Emily Nash Smyth, PharmD <i>Eli Lilly and Company</i>	Real-world Treatment (tx) Patterns and Outcomes for First-Line (1L) Novel Hormonal Agent (NHA) Naïve Metastatic Castration Resistant Prostate Cancer (mCRPC) Including in Black and/or African American (BAA) Patients (Pts)	Samuel Whipple, MSPH; Mark Guintier, PhD; Nadine Haddad, PhD; Wenxian Piao, PhD; Zhanglin Cui, PhD; Arjun Balar, PhD	Outcomes and Health Services Research
117	Jerry Kenmoe, MD <i>McLaren Flint Hospital</i>	Re-evaluating Breast Cancer Screening Recommendations: An Analysis of Breast Cancer Incidence by Age groups	Calvin Ghimire, MD; Harneet Ghumman, MD; Jores Kenmoe, MD; Tejaswi Vinjam, MD; Arvind Kunadi, MD	Epidemiology/Risks/Prevention
118	Ronscardy Mondesir, BA <i>Miami Cancer Institute</i>	Length of Hospital Stay, Unplanned Readmission and Mortality for Patients Treated with Partial Nephrectomy or Radical Nephrectomy for Stage I And II Kidney Tumors	Daniel Boaretto, BS; Nathan VanderVeer-Harris, BS; Dianelis Gonzalez Pupo, BA; Pushan Prabhakar, MBBS; Arjun Pon Avudaiappan, MS, MCh; Ahmed Eldefrawy, MD; Murugesan Manoharan, MD; Jorge Caso, MD; Ronscardy Mondesir, BA	Clinical Oncology
119	David Wei, PhD <i>Novartis Pharmaceuticals Corporation</i>	Non-optimal Treatment in Early line Patients With Chronic Myeloid Leukemia in Chronic Phase (CML-CP) Treated with Tyrosine Kinase Inhibitors (TKI): A Claims Data Analysis	David Wei, PhD; Daisy Yang, PharmD; Hela Romdhani, PhD; Dominick Latremouille-Viau, MA; Annie Guérin, MSc; Kejal Jadhav, MSc	Outcomes and Health Services Research
120	Pushan Prabhakar, MBBS <i>Miami Cancer Institute</i>	Surgeon Administered Transversus Abdominis Plane Block with Local Anesthetic Infiltration Versus Transversus Abdominis Plane Block Following Robot-Assisted Radical Prostatectomy	Arjun Pon Avudaiappan, MS, MCh; Daniel Ajabshir, BS; Orlando Brito Martinez, MD; Ahmed Eldefrawy, MD; Jorge Caso, MD; Murugesan Manoharan, MD	Clinical Oncology
121	Michael Imeh, MBBS <i>Lincoln Medical Center</i>	Impact of Frailty on Hospital Outcomes Among Patients with Hemophagocytic Lymphohistiocytosis Who Received Autologous Stem Cell Transplantation in the United States	Ani Gvajaja, MD; Chukwunonye Amaeshi, MBBS; Chiamaka Nwachukwu, MBBS; Fidelis Uwumiro, MBBS	Outcomes and Health Services Research
122	Ayobami Olafimihan, MD <i>John H. Stroger Jr. Hospital of Cook County</i>	Trends in the Incidence and Mortality of Metastatic Epidural Spinal Cord Compression: A Ten-Year Population-Based Study	Inimfon Jackson, MD, MPH, PhD; Stanley Ozogbo, MD, MPH; Jeremiah Bello, MD; Praise Fawehinmi, BSc; Hafeez Shaka, MD	Epidemiology/Risks/Prevention
123	Edward Li, PharmD, MPH <i>Sandoz Inc.</i>	Chemotherapy-Induced Febrile Neutropenia (FN) in the US: Healthcare Resource Utilization (HCRU) and Costs	Marie Yasuda, PharmD, MS; Jeanine Flanigan, PharmD, MS; Chi-Chang Chen, MSPH, PhD	Outcomes and Health Services Research
124	Lisa Tesoriero, MSN <i>Memorial Sloan Kettering Cancer Center</i> NCCN Member Institution	Standardizing Height and Weight Measurement for Treatment Calculations in Adult Patients with Cancer	Elizabeth Rodriguez, DNP; MaryAnn Connor, MSN; Jericho Garcia, MSN; Tiffany Lin, MPH; Mark Robson, MD; Tiffany Traina, MD; Karen Collum, DNP	Quality Improvement
125	Ana M. Barragan, MD, PhD <i>Universidad Del Rosario</i>	Serum Pepsinogen I/II in Patients Undergoing Esophagogastroduodenoscopy and Biopsy in Two Institutions in Bogotá, Colombia	Andres Isaza-Restrepo, MD, MSc; Geovanny Hernandez-Celi, MD; Viviana Marcela Hidalgo-Mora, MD; Joon Kung Whang, MD; Danna Lesley Cruz Reyes, PhD	Epidemiology/Risks/Prevention
126	Yanal Alnimer, MD, MPH <i>Markey Cancer Center</i>	The Effect of TBI Based Conditioning Regimen on Recurrence and Transplant Related Mortality Among Patients with Mantle Cell Lymphoma who Received Autologous Bone Marrow Transplant	Feviz F. Yalniz, MD; Chaitanaya Iragavarapu, MD; Reshma Ramlal, MD; Reinhold Munker, MD; Ayman Qasrawi, MD	Clinical Oncology
127	Lindsey Behlen Cotton, DO, MS <i>DELFI Diagnostics</i>	Utilizing Diverse Enrollment to Validate the DELFI Fragmentome Test for Advancing Lung Cancer Screening	Peter B. Bach, MD; Caitlin A Schonewolf, MD, MS; Demetria Tennefoss, DNP; Niti Trivedi, MPH; Chris Cisar, BS	Outcomes and Health Services Research
128	Jason Alter, PhD <i>Exosome Diagnostics</i>	Prostate Biopsies Against Medical Advice: Unveiling New Biomarker Insights for Men	Sonia Kumar, PhD; Johan Skog, PhD; Vinita Verma, MPH; Kyle Schimizzi, BS; Yiyuan Yao, MS; Christian J. Ray, PhD; Brian Haynes, PhD; Ronald Tutrone, PhD	Best Practices in Implementation and Use of Clinical Practice Guidelines
129	Shradha Parameswaran, MBBS, MD <i>Madras Medical College</i>	Plexus brachialis A Dosimetric Study in Carcinoma Head and Neck Treated Using Conformal Radiotherapy	Jyothish K.C., MBBS MDRT; Jeeva S., MBBS MDRT	Clinical Oncology

General Poster Sessions | Session II | Saturday, April 6 *continued*

#	Presenting Author and Institution	Title	Co-Authors	Category
130	John Kelvin Lalusis, MD <i>Saint Luke's Medical Center Global City</i>	Neoadjuvant Tyrosine Kinase Inhibitors (TKIs) Efficacy in EGFR Positive Stage III Nonsmall Cell Lung Cancer (NSCLC): A Systematic Review and Meta-Analysis	John Lois Padayao, MD	Clinical Oncology
131	Elizabeth Marrett, MPH <i>Daiichi Sankyo Inc</i>	Determinants of Quality of Life and Optimism in Patients with EGFR Mutated Advanced Non-small Cell Lung Cancer	Shaloo Gupta, MS; Kushal Modi, MS; Song Li, PhD; Jillian Rowen, BA; Jackie Kwong, PhD	Outcomes and Health Services Research
132	Krishna Desai, MD <i>Mercy Fitzgerald Hospital</i>	Epidemiological and Survival Analysis of Hemangiosarcoma in the Last Twenty Years	Yu Yu Thar, MD; Sabah Iqbal, MD; Manzoor Rather, MD; Rajesh Thirumaran, MD	Epidemiology/Risks/Prevention
133	Jiping Chen, RN <i>First Hospital of Qinhuangdao</i>	Evaluation of Aromatherapy with Lavender Oil During the Perioperative Period of Benign Prostate Hyperplasia: A Randomized Placebo Controlled Clinical Observation	Lijun Tang, MD, PhD	Clinical Oncology
134	Grace Allen, MSN, OCN <i>MemorialCare Health System</i>	Improving Adherence to Safe Handling of Oral Hazardous Drugs and Contaminated Wastes Guidelines	Grace Allen, MSN, OCN; Sadeeka Al-Majid, PhD, RN	Best Practices in Implementation and Use of Clinical Practice Guidelines
135	Erica Fortune, PhD <i>Cancer Support Community</i>	Patient Experiences and Perceptions of Biomarker Testing in AML and CML: A Qualitative Analysis	Abigail Newell, PhD; Maria Gonazlo, MS; Madyson Popalis, MPH; Elif Andac-Jones, PhD	Outcomes and Health Services Research
136	Aylin Yucel, PhD <i>Evidera Inc.</i>	Value of Early Transfusion Burden Reduction in Lower-Risk Myelodysplastic Syndromes (LR-MDS)	Sven L. Klijn, MSc; Hong Xiao, PhD; Benjamin White, MSc; Conrado Franco-Villalobos, MSc; Alina Sichevaya, BA; Ahmed Hnoosh, MSc; Dimana Miteva, PhD; Aylin Yucel, PhD	Outcomes and Health Services Research
137	Sakditad Saowapa, MD <i>Texas Tech University Health Sciences Center School of Medicine</i>	Evaluating Kaposi Sarcoma in Kidney Transplant Patients: A Systematic Review and Meta-Analysis	Natchaya Polpichai, MD; Pharit Siladech, MD; Chalothorn Wannaphut, MD; Manasawee Tanariyakul, MD; Phuuwadith Wattanachayakul, MD; Pakin Lalitnithi, MD	Clinical Oncology
138	Dominique Lopez, BS <i>Miami Cancer Institute</i>	Partial versus Radical Nephrectomy: An Age-Wise Comparison of the National Cancer Database	Daniel Boaretto, BS; Armin Ghomeshi, BS; Dominique Lopez, BS; Pushan Prabhakar, MBBS; Arjun Pon Avudaiappan, MS, MCh; Ahmed Eldefrawy, MD; Murugesan Manoharan, MD; Jorge Caso, MD	Clinical Oncology
139	Chi-Yin Liao, PhD <i>Eli Lilly and Company</i>	Intentional Weight Loss and Associated Cancer Incidence Among Patients With Overweight or Obesity: A Systematic Literature Review	Kristin M. Sheffield, PhD; Meredith M. Hoog, MPH; David Schapiro, PharmD; Raghuvir Keni, PhD; Wambui Grace Gathirua-Mwangi, PhD; Hong Kan, PhD	Epidemiology/Risks/Prevention
140	Insija Ilyas Selene, MD <i>University of Kentucky College of Medicine</i>	Role of Cyoreductive Nephrectomy in Metastatic Renal Cell Carcinoma in the Era of Immunotherapy: An Analysis of the National Cancer Database (NCDB)	Sven L. Klijn, MSc; Hong Xiao, PhD; Benjamin White, MSc; Conrado Franco-Villalobos, MSc; Alina Sichevaya, BA; Ahmed Hnoosh, MSc; Dimana Miteva, PhD; Aylin Yucel, PhD	Clinical Oncology
141	Saroj Prasad Sah, MS <i>Max Institute of Cancer Care Saket, New Delhi</i>	Oncological Outcome of Multimodality Treatment in Ewing Sarcoma	N/A	Outcomes and Health Services Research
142	Ruixuan Jiang, PharmD, PhD <i>Merck & Co Inc.</i>	Real-World Clinical Outcomes in Patients With Advanced/Metastatic Melanoma and Brain Metastases Treated With Pembrolizumab Monotherapy – An Analysis of the ADOReg German Skin Cancer Registry	Michael Weichenthal, MD, PhD; Cesar I. Fernandez-Lazaro, PhD, MPH, PharmD; Anja Rudolph, MSc, PhD; Clemens Krepler, MD; Peter Mohr, MD, PhD	Outcomes and Health Services Research
143	Ilene Trinh, BS <i>Case Comprehensive Cancer Center/ University Hospitals Seidman Cancer Center and Cleveland Clinic Taussig Cancer Institute</i> NCCN Member Institution	Analysis of Risk of Bone Fracture and Osteoporosis and Dual-Energy X-Ray Absorptiometry Screening Rates in Lung Cancer Survivors with and without Bone Metastases	Jaime Abraham Perez, PhD; Elleson Harper, BS; Lauren Chiec, MD; Qian Wang, MD, MPH; Melinda Hsu, MD, MS	Epidemiology/Risks/Prevention
144	Harneet Ghumman, MD <i>McLaren Flint Hospital</i>	A Comprehensive Examination of Disparities in Metastatic Breast Cancer Incidence: Race, Income and Geography	Calvin Ghimire, MD; Harneet Ghumman, MD; Elizabeth Mikhail, MD; Jores Kenmoe, BS; Arvind Kunadi, MD	Epidemiology/Risks/Prevention
145	Charlotte Ezratty, MD <i>Icahn School of Medicine at Mount Sinai Department of Medicine</i>	Treatment Implications of Expanded Genetic Testing Guidelines for Patients with Breast Cancer: A Retrospective Quality Review	Alaina Kessler, MD, MPH; Paula Klein, MD	Best Practices in Implementation and Use of Clinical Practice Guidelines
146	Megan Adams <i>Ross University School of Medicine</i>	A Narrative Review on Geriatric Assessment and Outcomes in Diffuse Large B-cell Lymphoma: Differentiating Fit, Frail, and Unfit Patients	Iuliia Kovalenko, MD; Chandni Garg, MD; Megan Adams; Pam G. Khosla, MD	Outcomes and Health Services Research
147	Nicolás Felipe Camargo, MD <i>Fundación Universitaria Sanitas</i>	Characterization of Short-Term Surgical Outcomes in Laparoscopic Gastrectomy at a High-Volume Center in Latin America: 10 Years of Experience	Jorge Isaac Vargas, MD; Liliana María Suárez Olarte, MD; German Jimenez, MD; Raúl Enrique Guevara, MD; Wilmar Martin, MD; Nicolás Felipe Camargo, MD; Eduardo Espin Lanz, MD; Francisco Solano Perdomo, MD	Clinical Oncology
148	Eliane Vieira, BSN, RN-BC, OCN <i>MemorialCare Health System</i>	Temporary Toilet Lids Minimize Contamination of Bathroom Surfaces with Hazardous Drugs	Grace Allen, MSN, OCN; Sadeeka Al-Majid, PhD, RN, FAAN	Best Practices in Implementation and Use of Clinical Practice Guidelines

General Poster Sessions | Session II | Saturday, April 6 *continued*

#	Presenting Author and Institution	Title	Co-Authors	Category
149	Tomer Bar Noy, MD <i>Lady Davis Institute for Medical Research</i>	Impact of Obesity on Sentinel Lymph Node Mapping in Patients with Endometrial Intraepithelial Neoplasia Undergoing Robotic Surgery	Yossi Tzur, MD; Yoav Brezinov, MD; Emad Matanes, MD; Susie Lau, MD; Shannon Salvador, MD; Melica Nourmoussavi; Brodeur, MD, MSC; Walter Gotlieb, MD, PhD	Best Practices in Implementation and Use of Clinical Practice Guidelines
150	Brenda Patricia Garza Badillo, MD <i>Hospital Universitario Dr Jose Eleuterio Gonzalez</i>	Clinical and Epidemiological Characterization of the Oncologic Population in a Third Level Hospital in Northeastern Mexico	David Hernández Barajas, MD; José Luis González Vela, MD; Ileana Cecilia Reynosa Silva, MD; Luis Andrés González Torres, MD; Ana Patricia Sánchez Fonseca, MS	Epidemiology/Risks/Prevention
151	Jennifer Browning, MS, APRN-CNP, ACHPN <i>The Ohio State University Comprehensive Cancer Center – James Cancer Hospital and Solove Research Institute</i> NCCN Member Institution	Implementation of Therapeutic Touch in an Ambulatory Palliative Oncology Clinic	Janine Overcash, PhD, APRN-CNP, FAANP, FAAN; Robin Rosselet, DNP, APRN-CNP/CNS, AOCN; Diane Von Ah, PhD, RN, FAAN	Best Practices in Implementation and Use of Clinical Practice Guidelines
152	Patricia Elizabeth Litkowski, MD <i>Siteman Cancer Center at Barnes-Jewish Hospital and Washington University School of Medicine</i> NCCN Member Institution	Retrospective Analysis of 30-day Readmission Risk in Oncology Patients	Ningying Wu, MD, PhD; Lauren Jurkowski, MD; Yash Shah, MD; Anna McComas, RN, BSN; Olivia Aranha, MD, PhD	Quality Improvement
153	Jennifer Fernandez <i>McKesson Corporation</i>	The Impact of Prescription Drug Plan (Part D) Enrollment for Medicare Beneficiaries on Eligibility for Episodic Value-Based Care Model Participation and Total Cost of Care (TCOC) at a Community Oncology Network	John Albaugh; Lora Markley; Puneeth Indurlal; Lalan Wilfong, MD	Outcomes and Health Services Research
154	Taylor Baggarley BSN, RN, CBCN, OCN <i>Ochsner Health</i>	Administration of Goserelin at Alternative Anatomical Sites in Premenopausal Breast Cancer	Nikhil Manjunath, MD; Stacia Young, PharmD, MBA; Joan Cannon, PharmD, MBA; Taylor Baggarley, RN	Clinical Oncology
155	Puneeth Indural, MD, MS, MBBS <i>The US Oncology Network</i>	Novel Therapies in the Oncology Care Model: A Profile in Review	Lalan S. Wilfong, MD	Quality Improvement
156	Chalothorn Wannaphut, MD <i>John A. Burns School of Medicine</i>	The Role of Obesity in Influencing Patient Survival in Metastatic Renal Cell Carcinoma Patients Receiving Immunotherapy: A Systematic Review and Meta-analysis	Sakditad Saowapa, MD; Natchaya Polpichai, MD; Pharit Siladech, MD; Manasawee Tanariyakul, MD; Phuwadith Wattanachayakul, MD; Pakin Lalitnithi, MD	Clinical Oncology
157	Pablo Gutierrez, MD <i>Fundacion Universitaria de Ciencias de la Salud</i>	Clinical Behavior, Oncological Outcomes, and External Validation of the Gronchi Nomogram in Patients Diagnosed with Primary Retroperitoneal Sarcoma Treated at a Latin American Reference Center between 2009 – 2018	Sandra Diaz-Casas, Mauricio Garcia-Mora, Carlos Lehmann-Mosquera; Javier Angel-Aristizabal; Sergio Cervera-Bonilla; Ricardo Sanchez-Pedraza, MS; Carlos Duarte Torres	Best Practices in Implementation and Use of Clinical Practice Guidelines
158	Cho Han Chiang, MD, MMSc <i>Mount Auburn Hospital</i>	The Effect of Exercise on Cardiotoxicity in Women with Breast Cancer Receiving Anthracycline-Based Chemotherapy: A Systematic Review and Meta-analysis	Yu-Cheng Chang, MD; Yulin Haw, MD; Jia Yi Tan, MD; Cho-Hsien Chiang, MD; Yuan Ping Hsia, MD; Cho-Hung Chiang, MD	Epidemiology/Risks/Prevention
159	Dhauna Karam Prasad, MBBS, MD <i>Mayo Clinic Comprehensive Cancer Center</i> NCCN Member Institution	Prevalence of Anxiety and Depression in Newly-Diagnosed Breast Cancer Patients in Rural Minnesota	Mina Hanna, MD; Timothy F. Kozelsky, MD; Scott H. Okuno, MD	Outcomes and Health Services Research
160	Insija Ilyas Selene, MD <i>University of Kentucky College of Medicine</i>	Association Between Primary Tumor Size and Prognosis in De novo Metastatic Renal Cell Carcinoma in patients Who Underwent First Line Immunotherapy-based Therapy: Real World Data Analysis	Roshmita Bardhan, DO; Rani Jayswal; Amina Dhahri, MD; Jennifer C. Torres Yee, MD; Heidi L. Weiss, PhD; Zin Myint, MD; Kimberly D. Ratliff	Clinical Oncology
161	Derek Tang, PhD, MS <i>Bristol Myers Squibb</i>	Real-World (RW) Effectiveness of Erythropoiesis-Stimulating Agents (ESAs) after Luspatercept in Patients (pts) with Myelodysplastic Syndromes (MDS): A Retrospective Analysis of a Large Healthcare Claims Database in the United States	Rui Song, PhD; Samantha Staff, MS; Enrico Zanardo, PhD; Lynn Huynh, MPH, MBA, DrPH; Manasi Mohan, MS; Megan Pinaire, MPH; Derek Tang, PhD, MS; Mihran Yenikomshian, MBA; Victoria Barghout, MSPH; Adeola Y. Makinde, PhD; Kashyap Patel, MD	Outcomes and Health Services Research
162	Cheongin Im, MSN, RN <i>The University of Texas at Austin School of Nursing</i>	Mobile Health (mHealth) Interventions for Colorectal Cancer (CRC) Survivors: A Systematic Review	Megan C. Thomas Hebdon, PhD, DNP, RN, NP-C; Namuun E Clifford, MSN, RN, FNP; Carolyn Phillips, PhD, MSN, RN, AOCNP	Outcomes and Health Services Research
163	Lynn Abbott-McCloud, MA <i>Dusty Joy Foundation/LiveLung</i>	Reaching Unmet Needs of Lung Cancer Patients Through Hope Totes and Educational Meetings	N/A	Outcomes and Health Services Research
164	Ahmad Basharat, MD <i>Marshfield Clinic Health System</i>	Outcomes with Sacituzumab Govitecan in Metastatic Breast Cancer: A Systematic Review and Meta-Analysis	Jawad Noor, MD; Muhammad Fareed Khalid, MD; Muhammad Kashif Amin, MD; Mehnaz Nadeem, MD; Ahmad Basharat, MD; Michael Jaglal, MD	Clinical Oncology
165	Moazzam Shahzad, MD <i>Moffitt Cancer Center</i> NCCN Member Institution	Outcomes with Sacituzumab Govitecan in Metastatic Breast Cancer: A Systematic Review and Meta Analysis	Jawad Noor, MD; Muhammad Fareed Khalid, MD; Muhammad Kashif Amin, MD; Mehnaz Nadeem, MD; Ahmad Basharat, MD; Michael Jaglal, MD	Clinical Oncology

General Poster Sessions | Session II | Saturday, April 6 *continued*

#	Presenting Author and Institution	Title	Co-Authors	Category
166	Precious C. Ferguson, MSN, APRN, FNP-BC <i>Nova Southeastern University</i>	Effects of a Music-Based Intervention on Reducing Compassion Fatigue in Oncology Advanced Practice Providers	N/A	Quality Improvement
167	Kimberly Younger, BSEE; BSBME <i>University of Kansas School of Medicine</i>	Determining the Barriers to Colonoscopy in Patients with Positive Cologuard Test	Jacob Guernsey; Joseph W. LeMaster, MD, MPH; Daniel Parente, MD, PhD; Allen K. Greiner, MD, MPH; Jennifer L. Woodward, MD, MPH	Epidemiology/Risks/Prevention
168	Alexander Rabadi, MD <i>McLaren Flint Hospital</i>	Casting Light on Metastatic Kidney Cancer Survival: A Gender-Based Examination	Calvin Ghimire, MD; Alexander Rabadi, MD; Anjela Shrestha, MD; Arvind Kunadi, MD	Epidemiology/Risks/Prevention
169	Anjela Shrestha, MD <i>McLaren Flint Hospital</i>	Unveiling the Socioeconomic Gradient: Income-Linked trends in metastatic Kidney Cancer Survival	Calvin Ghimire, MD; Alexander Rabadi, MD; Anjela Shrestha, MD; Arvind Kunadi, MD	Epidemiology/Risks/Prevention
170	Nathan VanderVeer-Harris, BS <i>Miami Cancer Institute</i>	A Propensity Matched Survival Analysis Comparing Partial Versus Radical Nephrectomy in Patients with Metastatic Renal Cell Carcinoma: A National Cancer Database Study	Nathan VanderVeer-Harris, BS; Aden Swayze, BA; Ronscardy Mondesir, BA; Raghuram Reddy, BS; Pushan Prabhakar, MBBS; Arjun Pon Avudaiappan, MS, MCh; Ahmed Eldefrawy, MD; Murugesan Manoharan, MD; Jorge Caso, MD	Clinical Oncology
171	Mohammed Bilal Elahi, MBBS, MS, FRCS <i>Hull University Teaching Hospitals NHS Trust</i>	Outcome of Positron Emission Tomography –Computed Tomography Staging in Breast Cancer Patients Having Neo-adjuvant Systemic Therapy	Mohammed Bilal Elahi, MBBS, MS, FRCS; Naila Bint Ihsan, MBBS, MS, FRCS; Dorin Dumitru, MBBS, MS, FRCS; Brendan Wooller, MBBS, FRCSEd; Peter Kneeshaw, MD, MB ChB, FRCS; Kartikae Grover, MBBS, MS, FRCS	Outcomes and Health Services Research
172	Atharv Sharma, BE <i>ZS Associates</i>	Empirical Study to Estimate Real World Impact of Delay in Adjuvant Treatment on Healthcare Resource Utilization and Cost Burden	Arunav Saikia, MS; Atharv Sharma, BE; Priyanka Halder, MBA; Manu Prasad, MBA; Prabhakar Gaur, B. Tech in Computer Science; Venkata Sai Sumanth Pulluri, B. Tech in Mechanical; Stuti Jha, B. Tech	Best Practices in Implementation and Use of Clinical Practice Guidelines
173	Pritika Sharma, MBBS <i>Westchester Medical Center</i>	Our Approach to Patient Selection for Polatuzumab-Based Therapy in Advanced Diffuse Large B-Cell Lymphoma	Sreshta Paranji, MD; Amir Steinberg, MD	Best Practices in Implementation and Use of Clinical Practice Guidelines
174	Aaron I. Kurian, MD <i>McLaren Flint Hospital</i>	Evaluation of Framework for Colorectal Cancer Health Needs Assessment in North and Central Asian Countries	Rebecca Pratiti, MD; Olga Santiago, PhD	Epidemiology/Risks/Prevention
175	Julia Olsen, MS <i>Hologic Inc.</i>	Standalone Performance Evaluation of an Artificial Intelligence Breast Cancer Detection Tool on Consecutively Collected Biopsy Proven Breast Cancer and Screening Negative Tomosynthesis Cases	Ashwini Kshirsagar, PhD; Julia Olsen, MS; Chirag Parghi, MD, MBA	Outcomes and Health Services Research
176	Catherine Boldig <i>University of South Florida Morsani College of Medicine</i>	Precision Medicine Drivers in Non-Small Cell Lung Cancer Brain Metastases	Kimberly Boldig, DO; Sepideh Mokhtari, MD; Arnold Etame, MD	Clinical Oncology
177	Aakash Tripathi, BS <i>Moffitt Cancer Center</i> NCCN Member Institution	Unifying Multimodal Data, Time Series Analytics, and Contextual Medical Memory: Introducing MINDS as an Oncology-Centric Cloud-Based Platform	Asim Waqas, MS; Ghulam Rasool, PhD	Bioinformatics/Information Technology Sciences
178	Nikita Dahake, MD <i>Temple Health</i>	Determining the Most Appropriate FIT to Increase Colorectal Cancer Screening in the Community	Brianna Graham, MD; Gabrielle Gillow, MD; Shelby McNeilly, DO; Abraham Ifrah, MD; Manasa Vallabhaneni, MD; Christopher Grivas, MD; Rishab Khatri, MD; Claire Raab, MD	Quality Improvement
179	Charlotte Walmsley, MD <i>Beth Israel Deaconess Medical Center</i>	Pembrolizumab-induced Hemophagocytic Lymphohistiocytosis in a Patient with Breast Cancer: A Case Report and Systematic Review of the Literature	Michael Andersen Jr., MD; Barbara Lam, MD; Deepa Rangachari, MD; Shana Berwick, MD; Rushad Patell, MD	Case Reports
180	Carrie Sha, MD; Marie Liu, MD <i>New York-Presbyterian Weill Cornell Medical Center</i>	Immunotherapy in Older Patients with Breast Cancer: Case Study and Literature Review	Marie Liu, MD; Diana Lake, MD; Jasmeet Singh, MD; Wanqing Iris Zhi, MD, PhD	Case Reports
181	Rachel Truong, MD <i>Orlando Regional Medical Center</i>	Liver-ing on a Prayer: A Rare Case of Hepatocellular Carcinoma with Metastasis to the Thyroid	Odelvys Granela, DO; Shelby Ploucher, MD; Alyssa Obermiller, DO; Van Anh T. Do, MD; Brian Shaw, DO; Jacqueline N. Kropf, DO	Case Reports
182	Anas Alqam, MD <i>University of Kansas School of Medicine Wichita</i>	Navigating the Challenges of NUT Midline Carcinoma: A Case Study and Therapeutic Insights for an Aggressive Oncologic Enigma"	Phu V. Truong, MD, FACP	Case Reports
183	Myoungsuk Kim, PhD <i>The University of North Carolina at Chapel Hill</i>	Effects of Web-based Interventions on Quality of Life Among Patients with Breast Cancer: A Systematic Review and Meta-analysis of Randomized Controlled Trials	Myoungsuk Kim, PhD	Case Reports
184	John Sharp, MD <i>The Ohio State University Comprehensive Cancer Center - James Cancer Hospital and Solove Research Institute</i> NCCN Member Institution	Response to Dabrafenib and Trametinib in a Patient with an Uncommon Activating BRAF Mutation: A First in Metastatic Non-Small Cell Lung Cancer	Daniel Jones, MD, PhD; Julia Rotow, MD; Panos Fidiias, MD; Erin Bertino, MD; Dwight Owen, MD, MS	Case Reports

General Poster Sessions | Session II | Saturday, April 6 *continued*

#	Presenting Author and Institution	Title	Co-Authors	Category
185	Keval Yerigeri, MD <i>Case Comprehensive Cancer Center/ University Hospitals Seidman Cancer Center and Cleveland Clinic Taussig Cancer Institute NCCN Member Institution</i>	Hemochromatosis in an Adult Female with Previous Iron Deficiency Anemia on Iron Supplementation	N/A	Case Reports
186	Paridhi Ghai, MD <i>Bridgeport Hospital</i>	Unmasking the Unpredictable: Spontaneous Tumor Lysis Syndrome in Metastatic Breast Cancer – A Case Beyond Expectations	Amy Gates, MD	Case Reports
187	Sesha Sai Kanakamedala, MD <i>University of Central Florida</i>	Extrapulmonary Small Cell Carcinoma of Gallbladder Presenting as Acute Cholecystitis	Sesha Sai Kanakamedala, MD; Sarah Tinsley, MD; Jamal Mohsin, MD	Case Reports
188	Christine Jane Kurian, MD <i>Cooper University Health Care</i>	Complete Remission of Microsatellite Instability-High (MSI-H) Oligometastatic Poorly Differentiated Colon Adenocarcinoma after a Single Dose of Immunotherapy	Danny Markabawi, MD	Case Reports
189	Albert Jang, MD <i>Case Comprehensive Cancer Center/ University Hospitals Seidman Cancer Center and Cleveland Clinic Taussig Cancer Institute NCCN Member Institution</i>	Successful Management of Locally Advanced and Oligometastatic Urothelial Carcinoma with Pembrolizumab- based Induction Regimen Followed by Consolidative Radical Resection of the Primary Tumor: A Multi-institutional Case Series	N/A	Case Reports
190	Jorge Arche Prats, MD <i>Clinica INDISA</i>	Neuroendocrine Tumor of the Gallbladder: A Case Report and Literature Review	N/A	Case Reports
191	Macarena Stevenson Figueroa, MD <i>Clinica Alemana de Santiago SA</i>	Preoperative Assessment of Vulvar Melanoma Surgical Margins Using in Vivo RCM	Nelson Mauricio Lobos Guede, MD; Alex Castro Medina, MD; Macarena Stevenson Figueroa, MD	Case Reports
192	Natalia de la Puente Mota <i>Hospital Universitario Lucus Augusti</i>	Gluteal Metastasis of Intrahepatic Cholangiocarcinoma: Clinical Case and Literature Review	Yolanda Gómez Fandiño; Francisco Javier Anguita Ramos; María López López; Mariaclaudia Ocharán Puell; Belén López Carnero; Jorge González Ramírez; Adriana Fernández García; José Conde Vales	Case Reports
193	Kevin Fitzpatrick O'Sullivan, MD <i>Beth Israel Deaconess Medical Center</i>	Microgranular Acute Promyelocytic Leukemia Presenting as Recurrent Stroke and Isolated Neutropenia	Rushad Patell, MD; Jason Freed, MD	Case Reports
194	Junqing Liu, PhD, MSW <i>Merck and Co.</i>	Social Determinants of Health in Real-World Evidence Studies of Early-Stage Cancer Care: A Systematic Literature Review	Andrew Osterland, PharmD, MS; Sarah Markt, ScD, MPH; Arthur Sillah, PhD; Esther Renee Smith-Howell, PhD, RN; Gregory Patton, MD; Kashif Firozvi, MD; Andrew Osterland, PharmD, MS	Case Reports
195	Julie Williamson, MD <i>University of Utah Medical Center</i>	A Rare Case of Immune Checkpoint Inhibitor Induced Seronegative Myasthenia Gravis	Meenu Singh, MD	Case Reports
196	Nirmala Ghimirey, DO <i>Summa Health System - Akron Campus</i>	Microangiopathic Hemolytic Anemia as the Presenting Manifestation of Metastatic Breast Cancer	Phuong Uyen Vo, DO; James Dibb, DO; Jordan Hatch, DO; Sameer Mahesh, MD	Case Reports
197	Khushboo Lakhatariya, MBBS <i>Trumbull Regional Medical Center</i>	Rare case of a Paraneoplastic Cerebellar Ataxia Secondary to a Retroperitoneal Neuroendocrine Tumor of Unknown Origin	Fehmida Laxmidhar, MBBS; Mrunal Patel, MBBS	Case Reports
198	Aaron Charles Lobo, MD <i>Bridgeport Hospital</i>	Hyperfibrinolysis as the Primary Presenting Sign of Metastatic Prostate Cancer: A Diagnostic Challenge	Zeynep Busra Zengin, MD; Charles Kenworthy, MD, PhD; Anish Sharda, MD, MPH	Case Reports
199	Mrunal Patel, MBBS <i>Trumbull Memorial Hospital</i>	Brown Fat Adipose Tissue (BAT) Activation Mimicking Lymphoma-Associated Lymphadenopathy	Fehmida Laxmidhar, MBBS; Khushboo Lakhatariya, MBBS; Rushin Patel, MD	Case Reports

Save These Dates

SAVE THE DATES!

2024 Annual Congress:
Hematologic Malignancies™

NCCN

Friday, September 20 – Saturday, September 21, 2024

New York Marriott Marquis • New York, NY

NCCN.org/hem
Virtual attendance available

SAVE THE DATES!

NCCN **Annual 2025 Conference** **March 28 - 30**

NCCN 30th ANNIVERSARY

New location! Caribe Royale Orlando • Orlando, FL

Pre-Conference Program
NCCN 2025 Nursing Program: Advancing Oncology Nursing™
Thursday, March 27, 2025

NCCN.org/conference
Virtual attendance available



Education. Community. Empowerment.

Founded in 2010, LiveLung is on a mission to improve health outcomes by advancing lung cancer education, early detection, and compassion for people impacted by lung cancer.



livelung.org | [f @LiveLungandProsper](https://www.facebook.com/LiveLungandProsper) | [@LiveLung1](https://www.instagram.com/LiveLung1) | [@LiveLung](https://www.linkedin.com/company/LiveLung) | [@LiveLung](https://www.youtube.com/channel/UC...)

In-Person &
Virtual Meetings

Small Cell Lung
Cancer Group

Lung Cancer
Educational
Materials

Community
Education Events

Resource Bags for
Newly Diagnosed
Patients

Lung Cancer
Research &
Support Advocacy



NCCN Virtual Reimbursement Resource Room

Learn about patient assistance and reimbursement programs available.

Search by:

- Cancer Type or Supportive Care Indication
- Drug Name
- Reimbursement Program



NCCN
REIMBURSEMENT
RESOURCE

Access for FREE online or via the app!
NCCN.org/reimbursement

Help people
living with cancer.
You can provide support for
FREE RESOURCES
and **INNOVATIONS**
IN ONCOLOGY RESEARCH.

NCCNFoundation.org/Donate



Our network embraces all people touched by cancer - the diagnosed and their loved ones - empowering individuals to take control of their health through access to resources, and programs of support, education, wellbeing and hope.

MyGo2Support, 24/7 Digital Patient Support Mobile Platform

Individual & Group Support
(Apoyo emocional)

Nutrition Programs
(Educación de nutrición)

Mind & Body Classes
(Clases de salud)

Financial Assistance
(Asistencia financiera)

Educational Workshops
(Programas educativos)

Support4Families
(Apoyo para familias)

My Voice Matters: Treatment Decision Support
(Herramientas de apoyo a decisiones)


Resources & Referrals
(Recursos y referencias)

Closing the Cancer Care Gap.

Accepting caregiver and patient referrals nationwide.


3 Crossroads Drive, Bedminster, NJ 07921 | www.crossroads4hope.org | 908-658-5400

Transforming Lives. Redefining Possibilities.



Jazz Pharmaceuticals is a global biopharmaceutical company whose purpose is to innovate to transform the lives of patients and their families. We are dedicated to developing potentially life-changing medicines for people with serious diseases — often with limited or no therapeutic options.





NCCN Guidelines for Patients®

Access 70+ FREE cancer resources

- Acute Lymphoblastic Leukemia (adult)
- Acute Lymphoblastic Leukemia (pediatric)
- Acute Myeloid Leukemia
- Adolescent and Young Adult Cancer
- Adrenal Tumors
- Anal Cancer
- Anemia and Neutropenia: Low Red and White Blood Cell Counts
- Basal Cell Skin Cancer
- B-Cell Lymphomas: Diffuse Large B-Cell Lymphomas
- B-Cell Lymphomas: Follicular Lymphoma
- B-Cell Lymphomas: Mantle Cell Lymphoma
- B-Cell Lymphomas: Marginal Zone Lymphomas
- Bladder Cancer
- Blood Clots and Cancer
- Bone Cancer
- Brain Cancer: Gliomas
- Breast Cancer: DCIS Breast Cancer
- Breast Cancer: Inflammatory Breast Cancer
- Breast Cancer: Invasive Breast Cancer
- Breast Cancer: Metastatic Breast Cancer
- Breast Cancer Screening and Diagnosis
- Central Nervous System Cancers: Primary Central Nervous System Lymphoma
- Cervical Cancer
- Chronic Lymphocytic Leukemia
- Chronic Myeloid Leukemia
- Colon Cancer
- Colorectal Cancer Screening
- Distress During Cancer Care
- Esophageal Cancer
- Fatigue and Cancer
- Gallbladder and Bile Duct Cancers
- Gastrointestinal Stromal Tumors (GIST)
- Graft-Versus-Host Disease
- Head and Neck Cancers: Mouth Cancer
- Head and Neck Cancers: Nasopharyngeal Cancer
- Head and Neck Cancers: Throat Cancer
- Hodgkin Lymphoma
- Hodgkin Lymphoma in Children
- Immunotherapy Side Effects: CAR T-Cell Therapy
- Immunotherapy Side Effects: Immune Checkpoint Inhibitors
- Kidney Cancer
- Liver Cancer
- Lung Cancer Screening
- Malignant Pleural Mesothelioma
- Melanoma
- Multiple Myeloma
- Mycosis Fungoides/Sézary Syndrome
- Myelodysplastic Syndromes
- Myeloproliferative Neoplasms
- Nausea and Vomiting
- Neuroendocrine Tumors
- Non-Small Cell Lung Cancer: Early and Locally Advanced
- Non-Small Cell Lung Cancer: Metastatic
- Ovarian Cancer
- Palliative Care
- Pancreatic Cancer
- Peripheral T-Cell Lymphoma
- Primary Cutaneous Lymphomas
- Prostate Cancer: Advanced Stage
- Prostate Cancer: Early Stage
- Rectal Cancer
- Small Cell Lung Cancer
- Soft Tissue Sarcoma
- Squamous Cell Skin Cancer
- Stomach Cancer
- Survivorship Care for Cancer-Related Late and Long-Term Effects
- Survivorship Care for Healthy Living
- Systemic Mastocytosis
- Thyroid Cancer
- Uterine Cancer
- Waldenström Macroglobulinemia



Free access

[NCCN.org/patientguidelines](https://www.nccn.org/patientguidelines)
[NCCN.org/patient-translations](https://www.nccn.org/patient-translations)

Download the free app

[NCCN.org/apps](https://www.nccn.org/apps)

Free copies as available

[NCCN.org/free-copies](https://www.nccn.org/free-copies)

KEYTRUDA[®]

(pembrolizumab) Injection 100 mg

Visit the Merck Booth and Learn More About KEYTRUDA

- Approved indications
- Resources for health care professionals
- The Merck Access Program
- KEY+YOU Patient Support Program

